| Year |
Citation |
Score |
| 2020 |
Woodward WA, Barlow WE, Jagsi R, Buchholz TA, Shak S, Baehner F, Whelan TJ, Davidson NE, Ingle JN, King TA, Ravdin PM, Osborne CK, Tripathy D, Livingston RB, Gralow JR, et al. Association Between 21-Gene Assay Recurrence Score and Locoregional Recurrence Rates in Patients With Node-Positive Breast Cancer. Jama Oncology. PMID 31917424 DOI: 10.1001/Jamaoncol.2019.5559 |
0.406 |
|
| 2019 |
Gralow JR, Barlow WE, Paterson AHG, Miao JL, Lew DL, Stopeck AT, Hayes DF, Hershman DL, Schubert MM, Clemons M, Van Poznak CH, Dees EC, Ingle JN, Falkson CI, Elias AD, ... Livingston RB, et al. Phase III randomized trial of bisphosphonates as adjuvant therapy in breast cancer: S0307. Journal of the National Cancer Institute. PMID 31693129 DOI: 10.1093/Jnci/Djz215 |
0.503 |
|
| 2019 |
Segar JM, Reed D, Stopeck A, Livingston RB, Chalasani P. A Phase II Study of Irinotecan and Etoposide as Treatment for Refractory Metastatic Breast Cancer. The Oncologist. PMID 31383812 DOI: 10.1634/Theoncologist.2019-0516 |
0.495 |
|
| 2019 |
Mehta RS, Barlow WE, Albain KS, Vandenberg TA, Dakhil SR, Tirumali NR, Lew DL, Hayes DF, Gralow JR, Linden HH, Livingston RB, Hortobagyi GN. Overall Survival with Fulvestrant plus Anastrozole in Metastatic Breast Cancer. The New England Journal of Medicine. 380: 1226-1234. PMID 30917258 DOI: 10.1056/Nejmoa1811714 |
0.481 |
|
| 2018 |
Sucheston-Campbell LE, Clay-Gilmour AI, Barlow WE, Budd GT, Stram DO, Haiman CA, Sheng X, Yan L, Zirpoli G, Yao S, Jiang C, Owzar K, Hershman D, Albain KS, Hayes DF, ... ... Livingston RB, et al. Genome-wide meta-analyses identifies novel taxane-induced peripheral neuropathy-associated loci. Pharmacogenetics and Genomics. 28: 49-55. PMID 29278617 DOI: 10.1097/Fpc.0000000000000318 |
0.394 |
|
| 2018 |
Mehta R, Barlow W, Albain K, Vandenberg T, Dakhil S, Tirumali N, Lew D, Hayes D, Gralow J, Linden H, Livingston R, Hortobagyi G. Abstract PD5-07: A phase III randomized trial of anastrozole and fulvestrant versus anastrozole or sequential anastrozole and fulvestrant as first-line therapy for postmenopausal women with metastatic breast cancer: Final survival outcomes of SWOG S0226 Cancer Research. 78. DOI: 10.1158/1538-7445.Sabcs17-Pd5-07 |
0.396 |
|
| 2017 |
Budd GT, Barlow WE, Moore HCF, Hobday TJ, Stewart JA, Isaacs C, Salim M, Cho JK, Rinn K, Albain KS, Chew HK, Burton GV, Moore TD, Srkalovic G, McGregor BA, ... ... Livingston RB, et al. SWOG S0221 updated: Randomized comparison of chemotherapy schedules in breast cancer adjuvant therapy. Journal of Clinical Oncology. 35: 521-521. DOI: 10.1200/Jco.2017.35.15_Suppl.521 |
0.374 |
|
| 2017 |
Pelekanou V, Barlow WE, Wahlde Mv, Wasserman B, Lo Y, Hayes DF, Hortobagyi GN, Gralow J, Tripathy D, Livingston RB, Porter P, Nahleh ZA, Rimm DL, Pusztai L. Effects of neoadjuvant chemotherapy (NAC) on tumor infiltrating lymphocytes (TIL) and PD-L1 expression in the SWOG S0800 clinical trial. Journal of Clinical Oncology. 35: 519-519. DOI: 10.1200/Jco.2017.35.15_Suppl.519 |
0.303 |
|
| 2016 |
Potkul RK, Unger JM, Livingston RB, Crew KD, Wilczynski SP, Salomon CG, Smith BL, Wong L, Campbell DL, Einspahr DE, Anderson GL, Hershman D, Goodman GE, Brown PH, Meyskens FL, et al. Randomized trial of medroxyprogesterone acetate for the prevention of endometrial pathology from adjuvant tamoxifen for breast cancer: SWOG S9630. Npj Breast Cancer. 2: 16024. PMID 28721383 DOI: 10.1038/npjbcancer.2016.24 |
0.353 |
|
| 2016 |
Woodward WA, Barlow WE, Jagsi R, Buchholz TA, Shak S, Baehner F, Yoshizawa CN, Whelan TJ, Davidson NE, Ingle JN, King TA, Ravdin PM, Osborne CK, Tripathy D, Livingston RB, et al. The 21-Gene Recurrence Score and Locoregional Recurrence Rates in Patients With Node-Positive Breast Cancer Treated on SWOG S8814. International Journal of Radiation Oncology, Biology, Physics. 96: S146. PMID 27675638 DOI: 10.1016/J.Ijrobp.2016.06.354 |
0.429 |
|
| 2016 |
Nahleh ZA, Barlow WE, Hayes DF, Schott AF, Gralow JR, Sikov WM, Perez EA, Chennuru S, Mirshahidi HR, Corso SW, Lew DL, Pusztai L, Livingston RB, Hortobagyi GN. SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer. Breast Cancer Research and Treatment. PMID 27393622 DOI: 10.1007/S10549-016-3889-6 |
0.528 |
|
| 2016 |
Brown-Glaberman U, Marron M, Chalasani P, Livingston R, Iannone M, Specht J, Stopeck AT. Circulating Carbonic Anhydrase IX and Antiangiogenic Therapy in Breast Cancer. Disease Markers. 2016: 9810383. PMID 26941473 DOI: 10.1155/2016/9810383 |
0.425 |
|
| 2016 |
Hertz DL, Barlow WE, Kidwell KM, Albain KS, Vandenberg TA, Dakhil SR, Tirumali NR, Livingston RB, Gralow J, Hayes DF, Hortobagyi GN, Mehta RS, Rae JM. Fulvestrant decreases anastrozole drug concentrations when taken concurrently by patients with metastatic breast cancer treated on SWOG study S0226. British Journal of Clinical Pharmacology. PMID 26859101 DOI: 10.1111/Bcp.12904 |
0.43 |
|
| 2016 |
Currin E, Peterson LM, Schubert EK, Link JM, Krohn KA, Livingston RB, Mankoff DA, Linden HM. Temporal Heterogeneity of Estrogen Receptor Expression in Bone-Dominant Breast Cancer: 18F-Fluoroestradiol PET Imaging Shows Return of ER Expression. Journal of the National Comprehensive Cancer Network : Jnccn. 14: 144-7. PMID 26850484 DOI: 10.6004/Jnccn.2016.0017 |
0.376 |
|
| 2016 |
Shirts BH, Casadei S, Jacobson AL, Lee MK, Gulsuner S, Bennett RL, Miller M, Hall SA, Hampel H, Hisama FM, Naylor LV, Goetsch C, Leppig K, Tait JF, Scroggins SM, ... ... Livingston R, et al. Improving performance of multigene panels for genomic analysis of cancer predisposition. Genetics in Medicine : Official Journal of the American College of Medical Genetics. PMID 26845104 DOI: 10.1038/Gim.2015.212 |
0.365 |
|
| 2016 |
Albain KS, Unger JM, Livingston RB, Crew KD, Wilczynski SP, Salomon CG, Smith BL, Wong L, Campbell D, Einspahr DE, Anderson GL, Hershman DL, Goodman GE, Brown P, Meyskens FL, et al. Randomized trial of medroxyprogesterone acetate for prevention of endometrial pathology from adjuvant tamoxifen for breast cancer: SWOG S9630. Journal of Clinical Oncology. 34: 547-547. DOI: 10.1200/Jco.2016.34.15_Suppl.547 |
0.494 |
|
| 2016 |
Segar J, Baker A, MacKerricher W, Nagle R, Livingston R, Clarke K, Ley M, Viscusi R, Gonzalez V, LeBeau L, Chalasani P. Abstract P6-04-10: Clinicopathological and molecular characteristics of pleomorphic invasive lobular carcinoma of breast Cancer Research. 76. DOI: 10.1158/1538-7445.Sabcs15-P6-04-10 |
0.359 |
|
| 2016 |
Chalasani P, Nagy D, Livingston R, Weterings E, Nagle R, Singh S, Barnes M, Grogan T, Ridder R, Baker A, Kandavel S. Abstract P4-07-07: Evaluating Rad51/geminin protein expression as an indicator of homologous recombination deficiency in breast cancer models Cancer Research. 76. DOI: 10.1158/1538-7445.Sabcs15-P4-07-07 |
0.446 |
|
| 2016 |
Grow J, Choudhary G, Kuo P, Livingston R, Gonzalez V. Abstract P3-12-12: Incidence of internal mammary node, sternum, and manubrium failure as detected by FDG-18 PET/CT Cancer Research. 76. DOI: 10.1158/1538-7445.Sabcs15-P3-12-12 |
0.385 |
|
| 2016 |
Kadlubar S, Barlow W, Mehta R, Daniels J, Albain K, Vandengerg T, Dakhil S, Tirumali N, Lew D, Gralow J, Livingston R, Hortobagiyi G, Hayes D, Rae J. Abstract P3-07-64: Association between gene variants in SULT1A1 and UGT1A4 and disease outcomes in patients enrolled in SWOG S0226 and treated with anastrozole alone or in combination with fulvestrant for metastatic breast cancer Cancer Research. 76. DOI: 10.1158/1538-7445.Sabcs15-P3-07-64 |
0.307 |
|
| 2016 |
Zirpoli GR, McCann SE, Sucheston-Campbell LE, Hershman DL, Ciupak G, Davis W, Unger JM, Moore HCF, Stewart JA, Isaacs C, Hobday TJ, Salim M, Livingston RB, Hortobagyi GN, Gralow JR, et al. Abstract 3413: Supplement use and chemotherapy-induced peripheral neuropathy in breast cancer patients treated on SWOG study S0221 Cancer Research. 76: 3413-3413. DOI: 10.1158/1538-7445.Am2016-3413 |
0.453 |
|
| 2016 |
Larsen VL, Barlow WE, Yang JJ, Zhu Q, Hutchins LF, Kadlubar SA, Albain KS, Livingston RB, Rae JM, Yeh I, Ravdin PM, Martino S, Lyss AP, Osborne CK, Hortobagyi GN, et al. Abstract 2032: Germline genetic variants in GATA3 and breast cancer treatment outcomes in SWOG 8897 trial Cancer Research. 76: 2032-2032. DOI: 10.1158/1538-7445.Am2016-2032 |
0.428 |
|
| 2015 |
Cho E, Schwemm AK, Rubinstein LM, Stevenson PA, Gooley TA, Ellis GK, Specht JM, Livingston RB, Linden HM, Gadi VK. Adjuvant Metronomic CMF in a Contemporary Breast Cancer Cohort: What's Old Is New. Clinical Breast Cancer. 15: e277-85. PMID 26025883 DOI: 10.1016/J.Clbc.2015.04.002 |
0.542 |
|
| 2015 |
Chahal J, Stopeck A, Clarke K, Livingston RB, Chalasani P. Intravenous thiotepa for treatment of breast cancer-related leptomeningeal carcinomatosis: case series. Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. 36: 1691-3. PMID 25990104 DOI: 10.1007/S10072-015-2259-1 |
0.474 |
|
| 2015 |
Chalasani P, Marron M, Roe D, Clarke K, Iannone M, Livingston RB, Shan JS, Stopeck AT. A phase I clinical trial of bavituximab and paclitaxel in patients with HER2 negative metastatic breast cancer. Cancer Medicine. 4: 1051-9. PMID 25826750 DOI: 10.1002/Cam4.447 |
0.502 |
|
| 2015 |
Budd GT, Barlow WE, Moore HC, Hobday TJ, Stewart JA, Isaacs C, Salim M, Cho JK, Rinn KJ, Albain KS, Chew HK, Burton GV, Moore TD, Srkalovic G, McGregor BA, ... Livingston RB, et al. SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 33: 58-64. PMID 25422488 DOI: 10.1200/Jco.2014.56.3296 |
0.518 |
|
| 2015 |
Goyal U, Gonzalez VJ, Ley MLB, Chalasani P, Viscusi RK, Lebeau L, Livingston RB. Concurrent capecitabine and radiotherapy for high risk breast cancer. Journal of Clinical Oncology. 33. DOI: 10.1200/Jco.2015.33.15_Suppl.E12034 |
0.505 |
|
| 2015 |
Gralow J, Barlow WE, Paterson AHG, Lew D, Stopeck A, Hayes DF, Hershman DL, Schubert M, Clemons MJ, Poznak CHV, Dees EC, Ingle JN, Falkson CI, Elias AD, Messino MJ, ... Livingston RB, et al. Phase III trial of bisphosphonates as adjuvant therapy in primary breast cancer: SWOG/Alliance/ECOG-ACRIN/NCIC Clinical Trials Group/NRG Oncology study S0307. Journal of Clinical Oncology. 33: 503-503. DOI: 10.1200/Jco.2015.33.15_Suppl.503 |
0.517 |
|
| 2015 |
Nahleh ZA, Barlow WE, Hayes DF, Schott AF, Gralow JR, Perez EA, Sikov WM, Chennuru S, Mirshahidi H, Vidito S, Lew DL, Pusztai L, Livingston RB, Hortobagyi GN. Abstract P3-11-16: S0800: Nab-paclitaxel, doxorubicin, cyclophosphamide, and pegfilgrastim with or without bevacizumab in treating women with inflammatory or locally advanced breast cancer (NCI CDR0000636131) Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-P3-11-16 |
0.529 |
|
| 2015 |
Samuel S, Viscusi R, Waer A, Gonzalez V, Chalasani P, Hurst C, Larson E, Livingston R, Ley M. Abstract P2-13-27: Nipple sparing mastectomy: Risks of wound complication in the setting of neo-adjuvant or adjuvant chemotherapy and/or radiation therapy Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-P2-13-27 |
0.428 |
|
| 2015 |
Sucheston-Campbell L, Clay A, Barlow WE, Budd GT, Stram D, Haiman C, Yan L, Zirpoli G, Yao S, Hershman D, Albain KS, Hayes DF, Moore H, Hobday TJ, Stewart JA, ... ... Livingston RB, et al. Abstract 5489: A genome-wide association study identifies novel loci associated with taxane-related sensory neuropathy in breast cancer patients enrolled in a cooperative group clinical trial (SWOG S0221) Cancer Research. 75: 5489-5489. DOI: 10.1158/1538-7445.Am2015-5489 |
0.415 |
|
| 2015 |
Chahal J, Stopeck A, Clarke K, Livingston RB, Chalasani P. Intravenous thiotepa for treatment of breast cancer-related leptomeningeal carcinomatosis: case series Neurological Sciences. 36: 1691-1693. DOI: 10.1007/s10072-015-2259-1 |
0.373 |
|
| 2014 |
Chalasani P, Stopeck A, Clarke K, Livingston R. A pilot study of estradiol followed by exemestane for reversing endocrine resistance in postmenopausal women with hormone receptor-positive metastatic breast cancer Oncologist. 19: 1127-1128. PMID 25260365 DOI: 10.1634/Theoncologist.2014-0306 |
0.46 |
|
| 2014 |
Smerage JB, Barlow WE, Hortobagyi GN, Winer EP, Leyland-Jones B, Srkalovic G, Tejwani S, Schott AF, O'Rourke MA, Lew DL, Doyle GV, Gralow JR, Livingston RB, Hayes DF. Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 32: 3483-9. PMID 24888818 DOI: 10.1200/Jco.2014.56.2561 |
0.51 |
|
| 2014 |
Gralow JR, Barlow WE, Lew D, Dammann K, Somlo G, Rinn KJ, Vogel SJ, Wong L, Livingston RB, Hortobagyi GN. A phase II study of docetaxel and vinorelbine plus filgrastim for HER-2 negative, stage IV breast cancer: SWOG S0102. Breast Cancer Research and Treatment. 143: 351-8. PMID 24352574 DOI: 10.1007/S10549-013-2797-2 |
0.513 |
|
| 2014 |
Yao S, Sucheston LE, Zhao H, Barlow WE, Zirpoli G, Liu S, Moore HC, Thomas Budd G, Hershman DL, Davis W, Ciupak GL, Stewart JA, Isaacs C, Hobday TJ, Salim M, ... ... Livingston RB, et al. Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancer. The Pharmacogenomics Journal. 14: 241-7. PMID 23999597 DOI: 10.1038/Tpj.2013.32 |
0.426 |
|
| 2014 |
Gralow J, Barlow WE, Paterson AHG, Lew D, Stopeck A, Hayes DF, Hershman DL, Schubert M, Clemons M, Poznak CHV, Dees EC, Ingle JN, Falkson CI, Elias AD, Messino MJ, ... Livingston RB, et al. SWOG S0307 phase III trial of bisphosphonates as adjuvant therapy in primary breast cancer: Comparison of toxicities and patient-stated preference for oral versus intravenous delivery. Journal of Clinical Oncology. 32: 558-558. DOI: 10.1200/Jco.2014.32.15_Suppl.558 |
0.486 |
|
| 2014 |
Budd GT, Barlow WE, Moore HCF, Hobday TJ, Stewart JA, Isaacs C, Salim M, Cho JK, Albain KS, Rinn K, Chew HK, Burton GV, Moore TD, Srkalovic G, McGregor BA, ... ... Livingston RB, et al. Outcome of male patients and black patients enrolled in S0221, an intergroup chemotherapy study. Journal of Clinical Oncology. 32: 1016-1016. DOI: 10.1200/Jco.2014.32.15_Suppl.1016 |
0.368 |
|
| 2013 |
Barlow WE, Moore HC, Hobday TJ, Stewart JA, Isaacs C, Salim M, Cho JK, Rinn K, Albain KS, Chew HK, Burton GV, Moore TD, Srkalovic G, McGregor BA, Flaherty LE, Livingston RB, et al. S0221: Comparison of two schedules of paclitaxel as adjuvant therapy for breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: CRA1008. PMID 28136064 DOI: 10.1200/jco.2013.31.18_suppl.cra1008 |
0.348 |
|
| 2013 |
Chalasani P, Livingston R. Differential Chemotherapeutic Sensitivity for Breast Tumors With “BRCAness”: A Review Oncologist. 18: 909-916. PMID 23881989 DOI: 10.1634/Theoncologist.2013-0039 |
0.308 |
|
| 2013 |
Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Livingston RB, Davidson NE, Perez EA, Chavarri-Guerra Y, Cameron DA, Pritchard KI, Whelan T, Shepherd LE, Tu D. Impact of premenopausal status at breast cancer diagnosis in women entered on the placebo-controlled NCIC CTG MA17 trial of extended adjuvant letrozole. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 24: 355-61. PMID 23028039 DOI: 10.1093/Annonc/Mds330 |
0.402 |
|
| 2013 |
Budd GT, Barlow WE, Moore HCF, Hobday TJ, Stewart JA, Isaacs C, Salim M, Cho JK, Rinn K, Albain KS, Chew HK, Burton GV, Moore TD, Srkalovic G, McGregor BA, ... ... Livingston RB, et al. S0221: Comparison of two schedules of paclitaxel as adjuvant therapy for breast cancer. Journal of Clinical Oncology. 31. DOI: 10.1200/Jco.2013.31.15_Suppl.Cra1008 |
0.422 |
|
| 2013 |
Specht JM, Kurland BF, Linden HM, Gralow J, Gadi VK, Ellis GK, Rodler ET, Chai X, Eun J, Brown-Glaberman UA, Livingston RB. A phase II study evaluating the safety and efficacy of sunitinib with weekly paclitaxel followed by doxorubicin and daily oral cyclophosphamide plus G-CSF as neoadjuvant chemotherapy (NC) for locally advanced (LABC) or inflammatory breast cancer (IBC). Journal of Clinical Oncology. 31: 1090-1090. DOI: 10.1200/Jco.2013.31.15_Suppl.1090 |
0.422 |
|
| 2013 |
Brown-Glaberman UA, Specht JM, Iannone M, Kurland BF, Livingston RB, Stopeck A. Circulating biomarkers in patients receiving neoadjuvant chemotherapy combined with sunitinib for locally advanced breast cancer. Journal of Clinical Oncology. 31: 1089-1089. DOI: 10.1200/Jco.2013.31.15_Suppl.1089 |
0.44 |
|
| 2013 |
Chalasani P, Stopeck A, Clarke K, Livingston R. Abstract P1-14-02: Reversing endocrine resistance: A pilot study of estradiol followed by exemestane Cancer Research. 73. DOI: 10.1158/0008-5472.Sabcs13-P1-14-02 |
0.432 |
|
| 2013 |
Lee E, Lundberg T, Ley M, Waer A, Livingston R, Stopeck A, Chalasani P, Gonzalez V, LeBeau L, Rose J, Viscusi R. Abstract P1-12-03: Primary squamous cell carcinoma of the breast Cancer Research. 73. DOI: 10.1158/0008-5472.Sabcs13-P1-12-03 |
0.496 |
|
| 2013 |
Brown-Glaberman U, Chalasani P, Livingston R, Iannone M, Marron M, Specht J, Stopeck A. Abstract P1-03-01: Circulating CAIX as a biomarker in breast cancer Cancer Research. 73. DOI: 10.1158/0008-5472.Sabcs13-P1-03-01 |
0.431 |
|
| 2012 |
Mehta RS, Barlow WE, Albain KS, Vandenberg TA, Dakhil SR, Tirumali NR, Lew DL, Hayes DF, Gralow JR, Livingston RB, Hortobagyi GN. Combination anastrozole and fulvestrant in metastatic breast cancer. The New England Journal of Medicine. 367: 435-44. PMID 22853014 DOI: 10.1056/Nejmoa1201622 |
0.468 |
|
| 2012 |
Kurland BF, Gadi VK, Specht JM, Allison KH, Livingston RB, Rodler ET, Peterson LM, Schubert EK, Chai X, Mankoff DA, Linden HM. Feasibility study of FDG PET as an indicator of early response to aromatase inhibitors and trastuzumab in a heterogeneous group of breast cancer patients. Ejnmmi Research. 2: 34. PMID 22731662 DOI: 10.1186/2191-219X-2-34 |
0.409 |
|
| 2012 |
Schott AF, Barlow WE, Albain KS, Chew HK, L.Wade III J, Lanier KS, Lew DL, Hayes DF, Gralow JR, Livingston RB, Hortobagyi GN. Phase II trial of simple oral therapy with capecitabine and cyclophosphamide in patients with metastatic breast cancer: SWOG S0430 Oncologist. 17: 179-187. PMID 22267853 DOI: 10.1634/Theoncologist.2011-0235 |
0.516 |
|
| 2011 |
Budd GT, Barlow WE, Moore HC, Hobday TJ, Stewart JA, Isaacs C, Salim M, Cho JK, Rinn K, Albain KS, Chew HK, Burton GV, Moore TD, Srkalovic G, McGregor BA, ... Livingston RB, et al. First analysis of SWOG S0221: A phase III trial comparing chemotherapy schedules in high-risk early breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 1004. PMID 28020775 DOI: 10.1200/jco.2011.29.15_suppl.1004 |
0.347 |
|
| 2011 |
Livingston RB, Barlow WE, Kash JJ, Albain KS, Gralow JR, Lew DL, Flaherty LE, Royce ME, Hortobagyi GN. SWOG S0215: a phase II study of docetaxel and vinorelbine plus filgrastim with weekly trastuzumab for HER2-positive, stage IV breast cancer. Breast Cancer Research and Treatment. 130: 123-31. PMID 21826527 DOI: 10.1007/S10549-011-1698-5 |
0.512 |
|
| 2011 |
Sucheston LE, Zhao H, Yao S, Zirpoli G, Liu S, Barlow WE, Moore HC, Thomas Budd G, Hershman DL, Davis W, Ciupak GL, Stewart JA, Isaacs C, Hobday TJ, Salim M, ... Livingston RB, et al. Genetic predictors of taxane-induced neurotoxicity in a SWOG phase III intergroup adjuvant breast cancer treatment trial (S0221). Breast Cancer Research and Treatment. 130: 993-1002. PMID 21766209 DOI: 10.1007/S10549-011-1671-3 |
0.436 |
|
| 2011 |
Linden HM, Kurland BF, Peterson LM, Schubert EK, Gralow JR, Specht JM, Ellis GK, Lawton TJ, Livingston RB, Petra PH, Link JM, Krohn KA, Mankoff DA. Fluoroestradiol positron emission tomography reveals differences in pharmacodynamics of aromatase inhibitors, tamoxifen, and fulvestrant in patients with metastatic breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 4799-805. PMID 21750198 DOI: 10.1158/1078-0432.Ccr-10-3321 |
0.383 |
|
| 2011 |
Dunnwald LK, Doot RK, Specht JM, Gralow JR, Ellis GK, Livingston RB, Linden HM, Gadi VK, Kurland BF, Schubert EK, Muzi M, Mankoff DA. PET tumor metabolism in locally advanced breast cancer patients undergoing neoadjuvant chemotherapy: value of static versus kinetic measures of fluorodeoxyglucose uptake. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 2400-9. PMID 21364034 DOI: 10.1158/1078-0432.Ccr-10-2649 |
0.367 |
|
| 2011 |
Ganz PA, Land SR, Geyer CE, Cecchini RS, Costantino JP, Pajon ER, Fehrenbacher L, Atkins JN, Polikoff JA, Vogel VG, Erban JK, Livingston RB, Perez EA, Mamounas EP, Wolmark N, et al. Menstrual history and quality-of-life outcomes in women with node-positive breast cancer treated with adjuvant therapy on the NSABP B-30 trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 1110-6. PMID 21300930 DOI: 10.1200/Jco.2010.29.7689 |
0.426 |
|
| 2011 |
Ellis GK, Barlow WE, Gralow JR, Hortobagyi GN, Russell CA, Royce ME, Perez EA, Lew D, Livingston RB. Phase III comparison of standard doxorubicin and cyclophosphamide versus weekly doxorubicin and daily oral cyclophosphamide plus granulocyte colony-stimulating factor as neoadjuvant therapy for inflammatory and locally advanced breast cancer: SWOG 0012 Journal of Clinical Oncology. 29: 1014-1021. PMID 21220618 DOI: 10.1200/Jco.2009.27.6543 |
0.503 |
|
| 2011 |
Mehta R, Barlow W, Albain K, Vandenberg T, Dakhil S, Tirumali N, Lew D, Hayes D, Gralow J, Livingston R, Hortobagyi G. S1-1: A Phase III Randomized Trial of Anastrozole Versus Anastrozole and Fulvestrant as First-Line Therapy for Postmenopausal Women with Metastatic Breast Cancer: SWOG S0226. Cancer Research. 71. DOI: 10.1158/0008-5472.Sabcs11-S1-1 |
0.396 |
|
| 2011 |
Downey L, Livingston RB. Systemic treatment of metastatic breast cancer Breast Surgical Techniques and Interdisciplinary Management. 1039-1044. DOI: 10.1007/978-1-4419-6076-4_86 |
0.37 |
|
| 2010 |
Yao S, Barlow WE, Albain KS, Choi JY, Zhao H, Livingston RB, Davis W, Rae JM, Yeh IT, Hutchins LF, Ravdin PM, Martino S, Lyss AP, Osborne CK, Abeloff M, et al. Gene polymorphisms in cyclophosphamide metabolism pathway,treatment-related toxicity, and disease-free survival in SWOG 8897 clinical trial for breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 6169-76. PMID 21169260 DOI: 10.1158/1078-0432.Ccr-10-0281 |
0.446 |
|
| 2010 |
Swain SM, Jeong JH, Geyer CE, Costantino JP, Pajon ER, Fehrenbacher L, Atkins JN, Polikoff J, Vogel VG, Erban JK, Rastogi P, Livingston RB, Perez EA, Mamounas EP, Land SR, et al. Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer. The New England Journal of Medicine. 362: 2053-65. PMID 20519679 DOI: 10.1097/Ogx.0B013E318202211D |
0.506 |
|
| 2010 |
Specht JM, Kurland BF, Montgomery SK, Dunnwald LK, Doot RK, Gralow JR, Ellis GK, Linden HM, Livingston RB, Allison KH, Schubert EK, Mankoff DA. Tumor metabolism and blood flow as assessed by positron emission tomography varies by tumor subtype in locally advanced breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 2803-10. PMID 20460489 DOI: 10.1158/1078-0432.Ccr-10-0026 |
0.372 |
|
| 2010 |
Yao S, Barlow WE, Albain KS, Choi JY, Zhao H, Livingston RB, Davis W, Rae JM, Yeh IT, Hutchins LF, Ravdin PM, Martino S, Lyss AP, Osborne CK, Abeloff MD, et al. Manganese superoxide dismutase polymorphism, treatment-related toxicity and disease-free survival in SWOG 8897 clinical trial for breast cancer. Breast Cancer Research and Treatment. 124: 433-9. PMID 20309628 DOI: 10.1007/S10549-010-0840-0 |
0.473 |
|
| 2010 |
Harigopal M, Barlow WE, Tedeschi G, Porter PL, Yeh IT, Haskell C, Livingston R, Hortobagyi GN, Sledge G, Shapiro C, Ingle JN, Rimm DL, Hayes DF. Multiplexed assessment of the Southwest Oncology Group-directed Intergroup Breast Cancer Trial S9313 by AQUA shows that both high and low levels of HER2 are associated with poor outcome. The American Journal of Pathology. 176: 1639-47. PMID 20150438 DOI: 10.2353/Ajpath.2010.090711 |
0.45 |
|
| 2010 |
Downey L, Livingston RB, Koehler M, Arbushites M, Williams L, Santiago A, Guzman R, Villalobos I, Di Leo A, Press MF. Chromosome 17 polysomy without human epidermal growth factor receptor 2 amplification does not predict response to lapatinib plus paclitaxel compared with paclitaxel in metastatic breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 1281-8. PMID 20145176 DOI: 10.1158/1078-0432.Ccr-09-1643 |
0.457 |
|
| 2010 |
Albain KS, Barlow WE, Shak S, Hortobagyi GN, Livingston RB, Yeh IT, Ravdin P, Bugarini R, Baehner FL, Davidson NE, Sledge GW, Winer EP, Hudis C, Ingle JN, Perez EA, et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. The Lancet. Oncology. 11: 55-65. PMID 20005174 DOI: 10.1016/S1470-2045(09)70314-6 |
0.412 |
|
| 2010 |
Slovak ML, Bedell V, Lew D, Albain KS, Ellis GK, Livingston RB, Martino S, Perez EA, Hortobagyi GN, Sher D, Stock W. Screening for clonal hematopoiesis as a predictive marker for development of therapy-related myeloid neoplasia (t-MN) following neoadjuvant therapy for breast cancer: a Southwest Oncology Group study (S0012). Breast Cancer Research and Treatment. 119: 391-8. PMID 19851858 DOI: 10.1007/S10549-009-0597-5 |
0.459 |
|
| 2010 |
Schott AF, Lew D, Barlow WE, Albain KS, Chew HK, Wade JL, Lanier KS, Linden HM, Hortobagyi GN, Livingston RB. Simple oral therapy with capecitabine (CAPE) and cyclophosphamide (CPA) for metastatic breast cancer (MBC). Journal of Clinical Oncology. 28: 1006-1006. DOI: 10.1200/JCO.2010.28.15_SUPPL.1006 |
0.339 |
|
| 2010 |
Swain SM, Jeong JH, Geyer CE, Costantino JP, Pajon ER, Fehrenbacher L, Atkins JN, Polikoff J, Vogel VG, Erban JK, Rastogi P, Livingston RB, Perez EA, Mamounas EP, Land SR, et al. Chemotherapy induced amenorrhea as an indicator of better survival in early breast cancer Breast Care. 5: 365-366. DOI: 10.1159/000322294 |
0.477 |
|
| 2009 |
Albain KS, Barlow WE, Ravdin PM, Farrar WB, Burton GV, Ketchel SJ, Cobau CD, Levine EG, Ingle JN, Pritchard KI, Lichter AS, Schneider DJ, Abeloff MD, Henderson IC, Muss HB, ... Livingston RB, et al. Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial. Lancet. 374: 2055-63. PMID 20004966 DOI: 10.1016/S0140-6736(09)61523-3 |
0.492 |
|
| 2009 |
Ambrosone CB, Barlow WE, Reynolds W, Livingston RB, Yeh IT, Choi JY, Davis W, Rae JM, Tang L, Hutchins LR, Ravdin PM, Martino S, Osborne CK, Lyss AP, Hayes DF, et al. Myeloperoxidase genotypes and enhanced efficacy of chemotherapy for early-stage breast cancer in SWOG-8897. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 4973-9. PMID 19752340 DOI: 10.1200/Jco.2009.21.8669 |
0.495 |
|
| 2009 |
Choi JY, Barlow WE, Albain KS, Hong CC, Blanco JG, Livingston RB, Davis W, Rae JM, Yeh IT, Hutchins LF, Ravdin PM, Martino S, Lyss AP, Osborne CK, Abeloff MD, et al. Nitric oxide synthase variants and disease-free survival among treated and untreated breast cancer patients in a Southwest Oncology Group clinical trial. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 5258-66. PMID 19671875 DOI: 10.1158/1078-0432.Ccr-09-0685 |
0.468 |
|
| 2009 |
Livingston R. T1 N0 triple negative breast cancer: a bad actor. The Breast Journal. 15: 451-3. PMID 19671104 DOI: 10.1111/J.1524-4741.2009.00804.X |
0.371 |
|
| 2009 |
Albain KS, Swann RS, Rusch VW, Turrisi AT, Shepherd FA, Smith C, Chen Y, Livingston RB, Feins RH, Gandara DR, Fry WA, Darling G, Johnson DH, Green MR, Miller RC, et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet. 374: 379-86. PMID 19632716 DOI: 10.1016/S0140-6736(09)60737-6 |
0.507 |
|
| 2009 |
Tubbs R, Barlow WE, Budd GT, Swain E, Porter P, Gown A, Yeh IT, Sledge G, Shapiro C, Ingle J, Haskell C, Albain KS, Livingston R, Hayes DF. Outcome of patients with early-stage breast cancer treated with doxorubicin-based adjuvant chemotherapy as a function of HER2 and TOP2A status. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 3881-6. PMID 19620488 DOI: 10.1200/Jco.2008.20.1566 |
0.513 |
|
| 2009 |
Hershman DL, Unger JM, Barlow WE, Hutchins LF, Martino S, Osborne CK, Livingston RB, Albain KS. Treatment quality and outcomes of African American versus white breast cancer patients: Retrospective analysis of southwest oncology studies S8814/S8897 Journal of Clinical Oncology. 27: 2157-2162. PMID 19307504 DOI: 10.1200/Jco.2008.19.1163 |
0.417 |
|
| 2009 |
Ganz P, Land S, Geyer C, Costantino J, Pajon E, Fehrenbacher L, Atkins J, Polikoff J, Vogel V, Erban J, Livingston R, Perez E, Mamounas E, Wolmark N, Swain S. NSABP B-30: definitive analysis of quality of life (QOL) and menstrual history (MH) outcomes from a randomized trial evaluating different schedules and combinations of adjuvant therapy containing doxorubicin, docetaxel and cyclophosphamide in women with operable, node-positive breast cancer. Cancer Research. 69: 76. DOI: 10.1158/0008-5472.Sabcs-76 |
0.401 |
|
| 2009 |
Swain S, Jeong J, Geyer C, Costantino J, Pajon E, Fehrenbacher L, Atkins J, Polikoff J, Vogel V, Erban J, Livingston R, Perez E, Mamounas E, Ganz P, Land S, et al. NSABP B-30: definitive analysis of patient outcome from a randomized trial evaluating different schedules and combinations of adjuvant therapy containing doxorubicin, docetaxel and cyclophosphamide in women with operable, node-positive breast cancer. Cancer Research. 69: 75. DOI: 10.1158/0008-5472.Sabcs-75 |
0.429 |
|
| 2009 |
Woods R, Huang J, Livingston R, Grasso-LeBeau L, Hendershott K, Gruessner A, Mayo J, Lang J. Prognostic Factors and Long-Term Survivors in Inflammatory Breast Cancer. Cancer Research. 69: 4039-4039. DOI: 10.1158/0008-5472.Sabcs-09-4039 |
0.459 |
|
| 2009 |
Goss P, Ingle J, Martino S, Robert N, Muss H, Shepherd L, Pritchard K, Livingston R, Davidson N, Perez E, Cameron D, Whelan T, Palmer M, Tu D. Outcomes of Women Who Were Premenopausal at Diagnosis of Early Stage Breast Cancer in the NCIC CTG MA17 Trial. Cancer Research. 69: 13-13. DOI: 10.1158/0008-5472.Sabcs-09-13 |
0.419 |
|
| 2008 |
Livingston RB, Downey L, Di Leo A, Koehler M, Arbushites M, Williams L, Press MF. Evaluation of chromosome 17 (Chr-17) polysomy in HER2 FISH-negative metastatic breast cancer (MBC) patients enrolled in a randomized phase III study of paclitaxel and lapatinib. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 1006. PMID 27951393 DOI: 10.1200/Jco.2008.26.15_Suppl.1006 |
0.449 |
|
| 2008 |
Chew HK, Barlow WE, Albain K, Lew D, Gown A, Hayes DF, Gralow J, Hortobagyi GN, Livingston R. A Phase II Study of Imatinib Mesylate and Capecitabine in Metastatic Breast Cancer: Southwest Oncology Group Study 0338 Clinical Breast Cancer. 8: 511-515. PMID 19073506 DOI: 10.3816/Cbc.2008.N.062 |
0.53 |
|
| 2008 |
Bezjak A, Lee CW, Ding K, Brundage M, Winton T, Graham B, Whitehead M, Johnson DH, Livingston RB, Seymour L, Shepherd FA. Quality-of-life outcomes for adjuvant chemotherapy in early-stage non-small-cell lung cancer: results from a randomized trial, JBR.10. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 5052-9. PMID 18809617 DOI: 10.1200/Jco.2007.12.6094 |
0.457 |
|
| 2008 |
Dunnwald LK, Gralow JR, Ellis GK, Livingston RB, Linden HM, Specht JM, Doot RK, Lawton TJ, Barlow WE, Kurland BF, Schubert EK, Mankoff DA. Tumor metabolism and blood flow changes by positron emission tomography: relation to survival in patients treated with neoadjuvant chemotherapy for locally advanced breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 4449-57. PMID 18626006 DOI: 10.1200/Jco.2007.15.4385 |
0.403 |
|
| 2008 |
Blumenthal DT, Rankin C, Eyre HJ, Livingston RB, Spence AM, Stelzer KJ, Rushing EJ, Berger MS, Rivkin SE, Cohn AL, Petersdorf SH. External beam irradiation and the combination of cisplatin and carmustine followed by carmustine alone for the treatment of high-grade glioma: a phase 2 Southwest Oncology Group trial. Cancer. 113: 559-65. PMID 18521920 DOI: 10.1002/Cncr.23585 |
0.446 |
|
| 2008 |
Goss PE, Ingle JN, Pater JL, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, et al. Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 1948-55. PMID 18332475 DOI: 10.1200/Jco.2007.11.6798 |
0.456 |
|
| 2008 |
Ingle JN, Tu D, Pater JL, Muss HB, Martino S, Robert NJ, Piccart MJ, Castiglione M, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, et al. Intent-to-treat analysis of the placebo-controlled trial of letrozole for extended adjuvant therapy in early breast cancer: NCIC CTG MA.17. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 19: 877-82. PMID 18332043 DOI: 10.1093/Annonc/Mdm566 |
0.466 |
|
| 2008 |
Kash J, Barlow WE, Albain KS, Gralow JR, Lew D, Flaherty LE, Royce ME, Hortobagyi GN, Livingston RB. Phase II Southwest Oncology Group study of docetaxel and vinorelbine plus filgrastim with weekly trastuzumab for HER2-positive, stage IV breast cancer Journal of Clinical Oncology. 26: 1033-1033. DOI: 10.1200/JCO.2008.26.15_SUPPL.1033 |
0.322 |
|
| 2007 |
Tsao MS, Aviel-Ronen S, Ding K, Lau D, Liu N, Sakurada A, Whitehead M, Zhu CQ, Livingston R, Johnson DH, Rigas J, Seymour L, Winton T, Shepherd FA. Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non small-cell lung cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 25: 5240-7. PMID 18024870 DOI: 10.1200/Jco.2007.12.6953 |
0.401 |
|
| 2007 |
Downey L, Livingston R, Stopeck A. Diagnosing and treating breast cancer in elderly women: A call for improved understanding Journal of the American Geriatrics Society. 55: 1636-1644. PMID 17727649 DOI: 10.1111/J.1532-5415.2007.01369.X |
0.464 |
|
| 2007 |
Kanne JP, Mankoff DA, Baird GS, Minoshima S, Livingston RB. Gastric linitis plastica from metastatic breast carcinoma: FDG and FES PET appearances. Ajr. American Journal of Roentgenology. 188: W503-5. PMID 17515338 DOI: 10.2214/Ajr.05.0441 |
0.33 |
|
| 2007 |
Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, et al. Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA.17. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 25: 2006-11. PMID 17452676 DOI: 10.1200/Jco.2006.09.4482 |
0.409 |
|
| 2007 |
Pepe C, Hasan B, Winton TL, Seymour L, Graham B, Livingston RB, Johnson DH, Rigas JR, Ding K, Shepherd FA. Adjuvant vinorelbine and cisplatin in elderly patients: National Cancer Institute of Canada and Intergroup Study JBR.10. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 25: 1553-61. PMID 17442999 DOI: 10.1200/Jco.2006.09.5570 |
0.483 |
|
| 2007 |
Moore HC, Green SJ, Gralow JR, Bearman SI, Lew D, Barlow WE, Hudis C, Wolff AC, Ingle JN, Chew HK, Elias AD, Livingston RB, Martino S. Intensive dose-dense compared with high-dose adjuvant chemotherapy for high-risk operable breast cancer: Southwest Oncology Group/Intergroup study 9623. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 25: 1677-82. PMID 17404368 DOI: 10.1200/JCO.2006.08.9383 |
0.309 |
|
| 2007 |
Linden HM, Haskell CM, Green SJ, Osborne CK, Sledge GW, Shapiro CL, Ingle JN, Lew D, Hutchins LF, Livingston RB, Martino S. Sequenced compared with simultaneous anthracycline and cyclophosphamide in high-risk stage I and II breast cancer: final analysis from INT-0137 (S9313). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 25: 656-61. PMID 17308269 DOI: 10.1200/JCO.2006.07.0847 |
0.383 |
|
| 2007 |
Specht JM, Tam SL, Kurland BF, Gralow JR, Livingston RB, Linden HM, Ellis GK, Schubert EK, Dunnwald LK, Mankoff DA. Serial 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) to monitor treatment of bone-dominant metastatic breast cancer predicts time to progression (TTP). Breast Cancer Research and Treatment. 105: 87-94. PMID 17268819 DOI: 10.1007/S10549-006-9435-1 |
0.387 |
|
| 2007 |
Rusch VW, Giroux DJ, Kraut MJ, Crowley J, Hazuka M, Winton T, Johnson DH, Shulman L, Shepherd F, Deschamps C, Livingston RB, Gandara D. Induction chemoradiation and surgical resection for superior sulcus non-small-cell lung carcinomas: long-term results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 25: 313-8. PMID 17235046 DOI: 10.1200/Jco.2006.08.2826 |
0.486 |
|
| 2007 |
Gauthier I, Ding K, Winton T, Shepherd FA, Livingston R, Johnson DH, Rigas JR, Whitehead M, Graham B, Seymour L. Impact of hemoglobin levels on outcomes of adjuvant chemotherapy in resected non-small cell lung cancer: the JBR.10 trial experience. Lung Cancer (Amsterdam, Netherlands). 55: 357-63. PMID 17141357 DOI: 10.1016/J.Lungcan.2006.10.021 |
0.353 |
|
| 2007 |
Dunnwald L, Gralow J, Ellis G, Livingston R, Linden H, Specht J, Doot R, Lawton T, Barlow W, Mankoff D. Tumor metabolism, blood flow changes, and prognosis by positron emission tomography: A prospective cohort of locally advanced breast cancer patients Journal of Clinical Oncology. 25: 506-506. DOI: 10.1200/Jco.2007.25.18_Suppl.506 |
0.33 |
|
| 2006 |
Gown AM, Goldstein LC, Porter PL, Livingston RB, Tam S, Yeh I, Barlow WE, Gralow JR, Hayes DF. Multivariate analysis of expression of the microtubule-associated protein, tau, predicts improved progression free and overall survival in patients with metastatic HER-2-negative breast cancers treated with docetaxel and vinorelbine plus filgrastim. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 24: 543. PMID 27953704 DOI: 10.1200/jco.2006.24.18_suppl.543 |
0.368 |
|
| 2006 |
Chew HK, Barlow WE, Albain KS, Lew D, Budd GT, Allen G, Gralow J, Livingston R. SWOG 0338: A phase II trial of imatinib mesylate in combination with capecitabine in metastatic breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 24: 10529. PMID 27951812 DOI: 10.1200/jco.2006.24.18_suppl.10529 |
0.345 |
|
| 2006 |
Porter PL, Barlow WE, Yeh IT, Lin MG, Yuan XP, Donato E, Sledge GW, Shapiro CL, Ingle JN, Haskell CM, Albain KS, Roberts JM, Livingston RB, Hayes DF. p27(Kip1) and cyclin E expression and breast cancer survival after treatment with adjuvant chemotherapy. Journal of the National Cancer Institute. 98: 1723-31. PMID 17148774 DOI: 10.1093/Jnci/Djj467 |
0.438 |
|
| 2006 |
Gandara DR, Chansky K, Albain KS, Gaspar LE, Lara PN, Kelly K, Crowley J, Livingston R. Long-term survival with concurrent chemoradiation therapy followed by consolidation docetaxel in stage IIIB non-small-cell lung cancer: a phase II Southwest Oncology Group Study (S9504). Clinical Lung Cancer. 8: 116-21. PMID 17026812 DOI: 10.3816/Clc.2006.N.039 |
0.482 |
|
| 2006 |
Gilliam LK, Kohn AD, Lalani T, Swanson PE, Vasko V, Patel A, Livingston RB, Pickett CA. Capecitabine therapy for refractory metastatic thyroid carcinoma: a case series. Thyroid : Official Journal of the American Thyroid Association. 16: 801-10. PMID 16910885 DOI: 10.1089/Thy.2006.16.801 |
0.346 |
|
| 2006 |
Linden HM, Stekhova SA, Link JM, Gralow JR, Livingston RB, Ellis GK, Petra PH, Peterson LM, Schubert EK, Dunnwald LK, Krohn KA, Mankoff DA. Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 24: 2793-9. PMID 16682724 DOI: 10.1200/Jco.2005.04.3810 |
0.393 |
|
| 2006 |
Ingle JN, Tu D, Pater JL, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, et al. Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial. Breast Cancer Research and Treatment. 99: 295-300. PMID 16541302 DOI: 10.1007/S10549-006-9207-Y |
0.422 |
|
| 2006 |
Pepe C, Hasan B, Winton T, Seymour L, Pater J, Livingston R, Johnson D, Rigas J, Ding K, Shepherd F. Adjuvant chemotherapy in elderly patients: An analysis of National Cancer Institute of Canada Clinical Trials Group and Intergroup BR.10 Journal of Clinical Oncology. 24: 7009-7009. DOI: 10.1200/Jco.2006.24.18_Suppl.7009 |
0.459 |
|
| 2006 |
Linden HM, Stekhova S, Link JM, Livingston RB, Gralow JR, Ellis GK, Peterson LM, Schubert EK, Krohn KA, Mankoff DA. Understanding resistance to hormonal therapy in estrogen avid breast cancer Journal of Clinical Oncology. 24: 566-566. DOI: 10.1200/Jco.2006.24.18_Suppl.566 |
0.396 |
|
| 2005 |
Gralow J, Green S, Lew D, Barlow W, Dammann K, Somlo G, Rivkin S, Taylor S, Wong L, Livingston R. SWOG S0102: A phase II study of docetaxel (DOC) and vinorelbine (VNR) + filgrastim for HER-2 negative, stage IV breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 567. PMID 27946474 DOI: 10.1200/jco.2005.23.16_suppl.567 |
0.366 |
|
| 2005 |
Ellis GK, Thompson T, Linden HM, Rinn K, Murphy AE, Gralow JR, Livingston RB. Adjuvant weekly "AC+G" followed by weekly paclitaxel shows good efficacy in node-positive breast cancer at two years median follow-up. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 628. PMID 27946067 DOI: 10.1200/jco.2005.23.16_suppl.628 |
0.319 |
|
| 2005 |
Gauthier I, Ding K, Winton T, Shepherd F, Livingston R, Johnson DH, Rigas JR, Whitehead M, Graham B, Seymour L. Impact of hemoglobin (Hb) on outcomes of adjuvant chemotherapy (ACT) with cisplatin/vinorelbine in patients (pts) with completely resected non-small cell lung cancer (NSCLC) in JBR.10. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 7200. PMID 27944653 DOI: 10.1200/Jco.2005.23.16_Suppl.7200 |
0.444 |
|
| 2005 |
Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. Journal of the National Cancer Institute. 97: 1262-71. PMID 16145047 DOI: 10.1093/Jnci/Dji250 |
0.495 |
|
| 2005 |
Winton T, Livingston R, Johnson D, Rigas J, Johnston M, Butts C, Cormier Y, Goss G, Inculet R, Vallieres E, Fry W, Bethune D, Ayoub J, Ding K, Seymour L, et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. The New England Journal of Medicine. 352: 2589-97. PMID 15972865 DOI: 10.1056/Nejmoa043623 |
0.461 |
|
| 2005 |
Wakelee HA, Stephenson P, Keller SM, Wagner H, Herskovic A, Komaki R, Marks RS, Perry MC, Livingston RB, Johnson DH. Post-operative radiotherapy (PORT) or chemoradiotherapy (CPORT) following resection of stages II and IIIA non-small cell lung cancer (NSCLC) does not increase the expected risk of death from intercurrent disease (DID) in Eastern Cooperative Oncology Group (ECOG) trial E3590. Lung Cancer (Amsterdam, Netherlands). 48: 389-97. PMID 15893008 DOI: 10.1016/j.lungcan.2004.11.007 |
0.372 |
|
| 2005 |
Gaspar LE, Chansky K, Albain KS, Vallieres E, Rusch V, Crowley JJ, Livingston RB, Gandara DR. Time from treatment to subsequent diagnosis of brain metastases in stage III non-small-cell lung cancer: a retrospective review by the Southwest Oncology Group. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 2955-61. PMID 15860851 DOI: 10.1200/Jco.2005.08.026 |
0.394 |
|
| 2005 |
West HL, Crowley JJ, Vance RB, Franklin WA, Livingston RB, Dakhil SR, Giguere JK, Rivkin SE, Kraut M, Chansky K, Gandara DR. Advanced bronchioloalveolar carcinoma: a phase II trial of paclitaxel by 96-hour infusion (SWOG 9714): a Southwest Oncology Group study. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 16: 1076-80. PMID 15860488 DOI: 10.1093/Annonc/Mdi215 |
0.508 |
|
| 2005 |
Alam N, Shepherd FA, Winton T, Graham B, Johnson DH, Livingston R, Rigas J, Whitehead M, Ding K, Seymour L. Compliance with post-operative adjuvant chemotherapy in non-small cell lung cancer an analysis of National Cancer Institute of Canada and intergroup trial JBR. 10 and a review of the literature Lung Cancer. 47: 385-394. PMID 15713522 DOI: 10.1016/J.Lungcan.2004.08.016 |
0.54 |
|
| 2005 |
Dunnwald LK, Gralow JR, Ellis GK, Livingston RB, Linden HM, Lawton TJ, Barlow WE, Schubert EK, Mankoff DA. Residual tumor uptake of [99mTc]-sestamibi after neoadjuvant chemotherapy for locally advanced breast carcinoma predicts survival. Cancer. 103: 680-8. PMID 15637688 DOI: 10.1002/cncr.20831 |
0.336 |
|
| 2005 |
Pierce LJ, Hutchins LF, Green SR, Lew DL, Gralow JR, Livingston RB, Osborne CK, Albain KS. Sequencing of tamoxifen and radiotherapy after breast-conserving surgery in early-stage breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 24-9. PMID 15545669 DOI: 10.1200/JCO.2005.01.198 |
0.35 |
|
| 2005 |
Bearman SI, Green S, Gralow J, Barlow W, Hudis C, Wolff A, Ingle J, Hortobagyi G, Livingston R, Martino S. SWOG/Intergroup 9623: A phase III comparison of intensive sequential chemotherapy to high dose chemotherapy and autologous hematopoietic progenitor cell support (AHPCS) for primary breast cancer in women with ≥4 involved axillary lymph nodes Journal of Clinical Oncology. 23: 572-572. DOI: 10.1200/JCO.2005.23.16_SUPPL.572 |
0.338 |
|
| 2005 |
Gauthier I, Ding K, Winton T, Shepherd E, Livingston R, Johnson D, Rigas J, Whitehead M, Graham B, Seymour L. P-615 Do hemoglobin (Hb) levels influence outcomes of adjuvant chemotherapy (ACT) with cisplatin/vinorelbine in patients (pts) with completely resected non small cell lung cancer (NSCLC)? The JBR.10 trial experience Lung Cancer. 49. DOI: 10.1016/S0169-5002(05)81108-0 |
0.355 |
|
| 2005 |
Tsao M, Zhu C, Livingston R, Johnson D, Gandara D, Viallet J, Ding K, Seymour L, Winton T, Shepherd F. O-118 The significance of K-ras mutations in the Intergroup JBR.10 Trial on adjuvant chemotherapy in completely resected early stage non-small cell lung cancer (NSCLC) patients Lung Cancer. 49: S41. DOI: 10.1016/S0169-5002(05)80252-1 |
0.304 |
|
| 2005 |
Rusch V, Albain K, Turrisi A, Swann S, Shepherd F, Chen Y, Livingston R, Darling G, Cox J, Sause W. O-035 Phase III trial of concurrent chemotherapy and radiotherapy(CT/RT) vs CT/RT followed by surgical resection for stage IIIa(pN2)non-small cell lung cancer (NSCLC): Outcomes and implications for surgical management in North American Intergroup 0139 (RTOG 9309) Lung Cancer. 49. DOI: 10.1016/S0169-5002(05)80167-9 |
0.391 |
|
| 2005 |
Alam N, Shepherd FA, Winton T, Graham B, Johnson D, Livingston R, Rigas J, Whitehead M, Ding K, Seymour L. Erratum: Compliance with post-operative adjuvant chemotherapy in non-small cell lung cancer: An analysis of National Cancer institute of Canada and intergroup trial JBR.10 and a review of the literature (Lung Cancer (2005) 47 (385-394) DOI: 10.1016/j.lungcan.2004.08.016. Lung Cancer. 50: 283-284. DOI: 10.1016/J.Lungcan.2005.07.001 |
0.437 |
|
| 2004 |
Tam S, Gumerlock P, Galvin I, Kimura T, Livingston R, Thompson T, Gralow J. Beta-tubulin III isotype expression and response to anti-tubulin therapy in metastatic breast cancer (MBC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 2138. PMID 28016898 DOI: 10.1200/jco.2004.22.14_suppl.2138 |
0.301 |
|
| 2004 |
Winton TL, Livingston R, Johnson D, Rigas J, Cormier Y, Butts C, Ding K, Seymour L, Magoski N, Shepherd F. A prospective randomised trial of adjuvant vinorelbine (VIN) and cisplatin (CIS) in completely resected stage 1B and II non small cell lung cancer (NSCLC) Intergroup JBR.10. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 7018. PMID 28016266 DOI: 10.1200/jco.2004.22.14_suppl.7018 |
0.353 |
|
| 2004 |
Bellon JR, Livingston RB, Eubank WB, Gralow JR, Ellis GK, Dunnwald LK, Mankoff DA. Evaluation of the internal mammary lymph nodes by FDG-PET in locally advanced breast cancer (LABC). American Journal of Clinical Oncology. 27: 407-10. PMID 15289736 DOI: 10.1097/01.Coc.0000128869.19357.9B |
0.343 |
|
| 2004 |
Eubank WB, Mankoff D, Bhattacharya M, Gralow J, Linden H, Ellis G, Lindsley S, Austin-Seymour M, Livingston R. Impact of FDG PET on defining the extent of disease and on the treatment of patients with recurrent or metastatic breast cancer American Journal of Roentgenology. 183: 479-486. PMID 15269044 DOI: 10.2214/Ajr.183.2.1830479 |
0.355 |
|
| 2004 |
Keller SM, Vangel MG, Wagner H, Schiller JH, Herskovic A, Komaki R, Marks RS, Perry MC, Livingston RB, Johnson DH. Prolonged survival in patients with resected non-small cell lung cancer and single-level N2 disease. The Journal of Thoracic and Cardiovascular Surgery. 128: 130-7. PMID 15224032 DOI: 10.1016/J.Jtcvs.2003.11.061 |
0.46 |
|
| 2004 |
Yaziji H, Goldstein LC, Barry TS, Werling R, Hwang H, Ellis GK, Gralow JR, Livingston RB, Gown AM. HER-2 testing in breast cancer using parallel tissue-based methods. Jama. 291: 1972-7. PMID 15113815 DOI: 10.1001/Jama.291.16.1972 |
0.353 |
|
| 2004 |
McCune JS, Hatfield AJ, Blackburn AA, Leith PO, Livingston RB, Ellis GK. Potential of chemotherapy-herb interactions in adult cancer patients. Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer. 12: 454-62. PMID 14991387 DOI: 10.1007/S00520-004-0598-1 |
0.423 |
|
| 2004 |
Edelman MJ, Chansky K, Gaspar LE, Leigh B, Weiss GR, Taylor SA, Crowley J, Livingston R, Gandara DR. Phase II trial of cisplatin/etoposide and concurrent radiotherapy followed by paclitaxel/carboplatin consolidation for limited small-cell lung cancer: Southwest Oncology Group 9713. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 127-32. PMID 14701775 DOI: 10.1200/JCO.2004.06.070 |
0.389 |
|
| 2004 |
Loehrer PJ, Wang W, Aisner S, Bonomi P, Einhorn LH, Langer CJ, Green MR, Livingston RB, Johnson DH, Schiller J. Long-term follow-up of patients with locally advanced or metastatic thymic malignancies: The Eastern Cooperative Oncology Group (ECOG) experience Journal of Clinical Oncology. 22: 7050-7050. DOI: 10.1200/Jco.2004.22.90140.7050 |
0.444 |
|
| 2004 |
Winton TL, Livingston R, Johnson D, Rigas J, Cormier Y, Butts C, Ding K, Seymour L, Magoski N, Shepherd F. A prospective randomised trial of adjuvant vinorelbine (VIN) and cisplatin (CIS) in completely resected stage 1B and II non small cell lung cancer (NSCLC) Intergroup JBR.10 Journal of Clinical Oncology. 22: 7018-7018. DOI: 10.1200/Jco.2004.22.90140.7018 |
0.457 |
|
| 2003 |
Mankoff DA, Dunnwald LK, Gralow JR, Ellis GK, Schubert EK, Tseng J, Lawton TJ, Linden HM, Livingston RB. Changes in blood flow and metabolism in locally advanced breast cancer treated with neoadjuvant chemotherapy. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 44: 1806-14. PMID 14602864 |
0.359 |
|
| 2003 |
Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. The New England Journal of Medicine. 349: 1793-802. PMID 14551341 DOI: 10.1056/Nejmoa032312 |
0.476 |
|
| 2003 |
Keller SM, Vangel MG, Wagner H, Schiller J, Herskovic A, Komaki R, Gray R, Marks RS, Perry MC, Livingston RB, Johnson DH. Second primary tumors following adjuvant therapy of resected stages II and IIIa non-small cell lung cancer. Lung Cancer (Amsterdam, Netherlands). 42: 79-86. PMID 14512191 DOI: 10.1016/S0169-5002(03)00274-5 |
0.492 |
|
| 2003 |
Yen TW, Mann GN, Lawton TJ, Livingston RB, Anderson BO. An axillary recurrence of breast cancer following a negative sentinel lymph node biopsy. The Breast Journal. 9: 234-6. PMID 12752634 DOI: 10.1046/J.1524-4741.2003.09321.X |
0.352 |
|
| 2003 |
Gandara DR, Chansky K, Albain KS, Leigh BR, Gaspar LE, Lara PN, Burris H, Gumerlock P, Kuebler JP, Bearden JD, Crowley J, Livingston R. Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: phase II Southwest Oncology Group Study S9504. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 21: 2004-10. PMID 12743155 DOI: 10.1200/JCO.2003.04.197 |
0.346 |
|
| 2003 |
Citron ML, Berry DA, Cirrincione C, Hudis C, Winer EP, Gradishar WJ, Davidson NE, Martino S, Livingston R, Ingle JN, Perez EA, Carpenter J, Hurd D, Holland JF, Smith BL, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 21: 1431-9. PMID 12668651 DOI: 10.1200/Jco.2003.09.081 |
0.448 |
|
| 2003 |
Livingston R. Current and planned trials with capecitabine in adjuvant/neoadjuvant therapy of breast cancer. Oncology (Williston Park, N.Y.). 16: 29-32. PMID 12435177 |
0.422 |
|
| 2003 |
Turrisi A, Scott C, Rusch V, Albain K, Shepherd F, Smith C, Chen Y, Livingston R, Gandara D, Darling G, Johnson D, Green M. Randomized trial of chemoradiotherapy to 61 Gy [no S] versus chemoradiotherapy to 45 Gy followed by surgery [S] using cisplatin etoposide in stage IIIa non-small cell lung cancer (NSCLC): intergroup trial 0139, RTOG (9309) International Journal of Radiation Oncology*Biology*Physics. 57: S125-S126. DOI: 10.1016/S0360-3016(03)00826-5 |
0.311 |
|
| 2003 |
Beziak A, Winton T, Ding K, Graham B, Seymour L, Ayoub J, Livingston R, Vallieres E, Rigas J, Demmy T, Devore R, Kessler K. O-58 Quality of life in a trial of adjuvant chemotherapy for early stage completely resected non-small cell lung cancer (NCIC CTG BR.10) Lung Cancer. 41. DOI: 10.1016/S0169-5002(03)91716-8 |
0.412 |
|
| 2002 |
Mankoff DA, Dunnwald LK, Gralow JR, Ellis GK, Schubert EK, Charlop AW, Tseng J, Rinn KJ, Livingston RB. [Tc-99m]-sestamibi uptake and washout in locally advanced breast cancer are correlated with tumor blood flow. Nuclear Medicine and Biology. 29: 719-27. PMID 12381452 DOI: 10.1016/S0969-8051(02)00333-5 |
0.377 |
|
| 2002 |
Keller SM, Vangel MG, Adak S, Wagner H, Schiller JH, Herskovic A, Komaki R, Perry MC, Marks RS, Livingston RB, Johnson DH. The influence of gender on survival and tumor recurrence following adjuvant therapy of completely resected stages II and IIIa non-small cell lung cancer. Lung Cancer (Amsterdam, Netherlands). 37: 303-9. PMID 12234700 DOI: 10.1016/S0169-5002(02)00103-4 |
0.459 |
|
| 2002 |
Ellis GK, Livingston RB, Gralow JR, Green SJ, Thompson T. Dose-dense anthracycline-based chemotherapy for node-positive breast cancer Journal of Clinical Oncology. 20: 3637-3643. PMID 12202664 DOI: 10.1200/Jco.2002.12.113 |
0.464 |
|
| 2002 |
Albain KS, Crowley JJ, Turrisi AT, Gandara DR, Farrar WB, Clark JI, Beasley KR, Livingston RB. Concurrent cisplatin, etoposide, and chest radiotherapy in pathologic stage IIIB non-small-cell lung cancer: a Southwest Oncology Group phase II study, SWOG 9019. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 20: 3454-60. PMID 12177106 DOI: 10.1200/Jco.2002.03.055 |
0.516 |
|
| 2002 |
Mankoff DA, Dunnwald LK, Gralow JR, Ellis GK, Charlop A, Lawton TJ, Schubert EK, Tseng J, Livingston RB. Blood flow and metabolism in locally advanced breast cancer: relationship to response to therapy. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 43: 500-9. PMID 11937594 |
0.315 |
|
| 2002 |
Eubank WB, Mankoff DA, Vesselle HJ, Eary JF, Schubert EK, Dunnwald LK, Lindsley SK, Gralow JR, Austin-Seymour MM, Ellis GK, Livingston RB. Detection of locoregional and distant recurrences in breast cancer patients by using FDG PET. Radiographics : a Review Publication of the Radiological Society of North America, Inc. 22: 5-17. PMID 11796893 DOI: 10.1148/Radiographics.22.1.G02Ja055 |
0.363 |
|
| 2001 |
Gralow JR, Livingston RB. University of Washington High-Dose Cyclophosphamide, Mitoxantrone, and Etoposide Experience in Metastatic Breast Cancer: Unexpected Cardiac Toxicity Journal of Clinical Oncology. 19: 3903-3904. PMID 11559728 DOI: 10.1200/Jco.2001.19.18.3903 |
0.418 |
|
| 2001 |
Thomas CR, Giroux DJ, Janaki LM, Turrisi AT, Crowley JJ, Taylor SA, McCracken JD, Shankir Giri PG, Gordon W, Livingston RB, Gandara DR. Ten-year follow-up of Southwest Oncology Group 8269: a phase II trial of concomitant cisplatin-etoposide and daily thoracic radiotherapy in limited small-cell lung cancer. Lung Cancer (Amsterdam, Netherlands). 33: 213-9. PMID 11551416 DOI: 10.1016/S0169-5002(01)00181-7 |
0.513 |
|
| 2001 |
Livingston RB, Esteva FJ. Chemotherapy and Herceptin for HER-2+ Metastatic Breast Cancer: The Best Drug? Oncologist. 6: 315-316. PMID 11524548 DOI: 10.1634/Theoncologist.6-4-315 |
0.446 |
|
| 2001 |
Eubank WB, Mankoff DA, Takasugi J, Vesselle H, Eary JF, Shanley TJ, Gralow JR, Charlop A, Ellis GK, Lindsley KL, Austin-Seymour MM, Funkhouser CP, Livingston RB. 18Fluorodeoxyglucose Positron Emission Tomography to Detect Mediastinal or Internal Mammary Metastases in Breast Cancer Journal of Clinical Oncology. 19: 3516-3523. PMID 11481358 DOI: 10.1200/Jco.2001.19.15.3516 |
0.332 |
|
| 2001 |
Kelly K, Crowley J, Bunn PA, Presant CA, Grevstad PK, Moinpour CM, Ramsey SD, Wozniak AJ, Weiss GR, Moore DF, Israel VK, Livingston RB, Gandara DR. Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Vinorelbine Plus Cisplatin in the Treatment of Patients With Advanced Non–Small-Cell Lung Cancer: A Southwest Oncology Group Trial Journal of Clinical Oncology. 19: 3210-3218. PMID 11432888 DOI: 10.1200/Jco.2001.19.13.3210 |
0.488 |
|
| 2001 |
Loehrer PJ, Jiroutek M, Aisner S, Aisner J, Green M, Thomas CR, Livingston R, Johnson DH. Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma: an intergroup trial. Cancer. 91: 2010-5. PMID 11391579 DOI: 10.1002/1097-0142(20010601)91:11<2010::AID-CNCR1226>3.0.CO;2-2 |
0.325 |
|
| 2001 |
Gabrilove JL, Cleeland CS, Livingston RB, Sarokhan B, Winer E, Einhorn LH. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 19: 2875-82. PMID 11387360 DOI: 10.1200/JCO.2001.19.11.2875 |
0.321 |
|
| 2001 |
Keller SM, Adak S, Wagner H, Herskovic A, Komaki R, Brooks BJ, Perry MC, Livingston RB, Johnson DH. Analyse d’essais cliniquesA randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIa non-small-cell lung cancer Cancer Radiotherapie. 5. PMID 11355584 DOI: 10.1016/S1278-3218(00)00066-4 |
0.469 |
|
| 2001 |
Sause W, Kolesar P, Taylor S, Johnson D, Livingston R, Komaki R, Emami B, Curran W, Byhardt R, Dar R, Turrisi A. Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer Cancer Radiotherapie. 5: 206. DOI: 10.1016/S1278-3218(00)00076-7 |
0.414 |
|
| 2000 |
Keller SM, Adak S, Wagner H, Herskovic A, Komaki R, Brooks BJ, Perry MC, Livingston RB, Johnson DH. A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small-cell lung cancer. Eastern Cooperative Oncology Group. The New England Journal of Medicine. 343: 1217-22. PMID 11071672 DOI: 10.1056/Nejm200010263431703 |
0.513 |
|
| 2000 |
Yuen AR, Zou G, Turrisi AT, Sause W, Komaki R, Wagner H, Aisner SC, Livingston RB, Blum R, Johnson DH. Similar outcome of elderly patients in intergroup trial 0096: Cisplatin, etoposide, and thoracic radiotherapy administered once or twice daily in limited stage small cell lung carcinoma. Cancer. 89: 1953-60. PMID 11064352 DOI: 10.1002/1097-0142(20001101)89:9<1953::AID-CNCR11>3.0.CO;2-6 |
0.443 |
|
| 2000 |
Bellon JR, Lindsley KL, Ellis GK, Gralow JR, Livingston RB, Austin Seymour MM. Concurrent radiation therapy and paclitaxel or docetaxel chemotherapy in high-risk breast cancer. International Journal of Radiation Oncology, Biology, Physics. 48: 393-7. PMID 10974452 DOI: 10.1016/S0360-3016(00)00636-2 |
0.386 |
|
| 2000 |
Gutierrez-Delgado F, Holmberg LA, Hooper H, Appelbaum FR, Livingston RB, Maziarz RT, Weiden P, Rivkin S, Montgomery P, Kawahara K, Bensinger W. High-dose busulfan, melphalan and thiotepa as consolidation for non-inflammatory high-risk breast cancer Bone Marrow Transplantation. 26: 51-59. PMID 10918405 DOI: 10.1038/Sj.Bmt.1702461 |
0.49 |
|
| 2000 |
Sause W, Kolesar P, Taylor S IV, Johnson D, Livingston R, Komaki R, Emami B, Curran W, Byhardt R, Dar AR, Turrisi A. Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Chest. 117: 358-64. PMID 10669675 DOI: 10.1378/Chest.117.2.358 |
0.446 |
|
| 2000 |
Gandara DR, Lovato LC, Albain KS, Leigh B, Lara PN, Crowley JJ, Livingston RB. Pathologic stage IIIb non-small cell lung cancer (NSCLC): Prolonged survival with consoloidation Docetaxel following concurrent chemoradiotherapy (SWOG 9504) Lung Cancer. 29: 92-93. DOI: 10.1016/S0169-5002(00)80303-7 |
0.431 |
|
| 2000 |
Keller S, Adak S, Wagner H, Herskovic A, Brooks B, Perry M, Livingston R, Johnson D. Prospective randomized trial of postoperative adjuvant therapy in patients with completely resected stages II and IIIa non-small cell lung cancer: An intergroup trial (E3590) Lung Cancer. 29: 92. DOI: 10.1016/S0169-5002(00)80302-5 |
0.351 |
|
| 2000 |
Kelly K, Bunn PA, Lovato L, Crowley J, Livingston RB, Gandara DR. A phase II study of cisplatin, etoposide, and paclitaxel (PET) with G-CSF in untreated patients with extensive small cell lung cancer: A Southwest Oncology Group trial Lung Cancer. 29: 8. DOI: 10.1016/S0169-5002(00)80020-3 |
0.435 |
|
| 1999 |
Murray N, Livingston RB, Shepherd FA, James K, Zee B, Langleben A, Kraut M, Bearden J, Goodwin JW, Grafton C, Turrisi A, Walde D, Croft H, Osoba D, Ottaway J, et al. Randomized study of CODE versus alternating CAV/EP for extensive-stage small-cell lung cancer: an Intergroup Study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 17: 2300-8. PMID 10561291 DOI: 10.1200/Jco.1999.17.8.2300 |
0.481 |
|
| 1999 |
Ellis GK, Green S, Livingston RB, Kraut MJ, Pierce HI, Paradelo JC, Taylor SA, Martino S. 'Neo-FAC' (5-fluorouracil, doxorubicin, and cyclophosphamide) for poor-prognosis stage IV breast cancer: a Southwest Oncology Group Phase II Study. American Journal of Clinical Oncology. 22: 446-449. PMID 10521055 DOI: 10.1097/00000421-199910000-00004 |
0.5 |
|
| 1999 |
Leigh BR, Gandara DR, Crowley JJ, Furuse K, Livingston RB, Fukushima M, Coltman CA. Summary of the proceedings of the United States--Japan lung cancer clinical trials summit: San Francisco, CA, 20-22 November, 1998. Lung Cancer (Amsterdam, Netherlands). 24: 181-91. PMID 10460006 DOI: 10.1016/S0169-5002(99)00037-9 |
0.363 |
|
| 1999 |
Mankoff DA, Dunnwald LK, Gralow JR, Ellis GK, Drucker MJ, Livingston RB. Monitoring the response of patients with locally advanced breast carcinoma to neoadjuvant chemotherapy using [technetium 99m]-sestamibi scintimammography Cancer. 85: 2410-2423. PMID 10357412 DOI: 10.1002/(SICI)1097-0142(19990601)85:11<2410::AID-CNCR16>3.0.CO;2-K |
0.35 |
|
| 1999 |
Livingston RB. What is the role of radiation therapy in locally advanced non-small-cell lung cancer? Annals of Oncology. 10: 259-260. PMID 10355567 DOI: 10.1023/A:1008372400849 |
0.392 |
|
| 1999 |
Ellis GK, Gralow JR, Pierce HI, Williams MA, Livingston RB. Infusional Paclitaxel and Weekly Vinorelbine Chemotherapy With Concurrent Filgrastim for Metastatic Breast Cancer: High Complete Response Rate in a Phase I-II Study of Doxorubicin-Treated Patients Journal of Clinical Oncology. 17: 1407-1407. PMID 10334525 DOI: 10.1200/Jco.1999.17.5.1407 |
0.511 |
|
| 1999 |
Turrisi AT, Kim K, Blum R, Sause WT, Livingston RB, Komaki R, Wagner H, Aisner S, Johnson DH. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. The New England Journal of Medicine. 340: 265-71. PMID 9920950 DOI: 10.1056/Nejm199901283400403 |
0.51 |
|
| 1999 |
Bellon J, Lindsley K, Ellis G, Gralow J, Livingston R, Austin-Seymour M. 2061 Feasibility of concurrent radiation therapy and paclitaxel or docetaxel chemotherapy in the management of locally advanced breast cancer International Journal of Radiation Oncology*Biology*Physics. 45: 309. DOI: 10.1016/S0360-3016(99)90331-0 |
0.338 |
|
| 1999 |
Keller SM, Adak S, Wagner HJ, Herskovic A, Komaki R, Brooks BJ, Perry MC, Livingston RB, Johnson DH. 2 Randomized prospective comparison of adjuvant mediastinal radiation (RT) with or without concurrent chemotherapy with cisplatin and etoposide (PE) for patients with completely resected 51-3N1-2M0 non-small cell lung cancer (NSCLC): US International Journal of Radiation Oncology Biology Physics. 45: 145-146. DOI: 10.1016/S0360-3016(99)90020-2 |
0.468 |
|
| 1998 |
Lau DH, Crowley JJ, Gandara DR, Hazuka MB, Albain KS, Leigh B, Fletcher WS, Lanier KS, Keiser WL, Livingston RB. Southwest Oncology Group phase II trial of concurrent carboplatin, etoposide, and radiation for poor-risk stage III non-small-cell lung cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 16: 3078-81. PMID 9738578 DOI: 10.1200/Jco.1998.16.9.3078 |
0.457 |
|
| 1998 |
Wozniak AJ, Crowley JJ, Balcerzak SP, Weiss GR, Spiridonidis CH, Baker LH, Albain KS, Kelly K, Taylor SA, Gandara DR, Livingston RB. Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 16: 2459-65. PMID 9667264 DOI: 10.1200/Jco.1998.16.7.2459 |
0.489 |
|
| 1998 |
Thomas CR, Giroux DJ, Stelzer KJ, Craig JB, Laufman LR, Taylor SA, Goodwin JW, Crowley JJ, Livingston RB. Concurrent cisplatin, prolonged oral etoposide, and vincristine plus chest and brain irradiation for limited small cell lung cancer: a phase II study of the Southwest Oncology Group (SWOG-9229). International Journal of Radiation Oncology, Biology, Physics. 40: 1039-47. PMID 9539558 DOI: 10.1016/S0360-3016(98)00003-0 |
0.352 |
|
| 1998 |
Dunnwald LK, Mankoff DA, Ellis GK, Gralow JR, Drucker MJ, Livingston R. [Tc99m]-Sestamibi scintimammography to compare the efficacy of different neo-adjuvant chemotherapy regimens. Clinical Nuclear Medicine. 23: 491. DOI: 10.1097/00003072-199807000-00044 |
0.409 |
|
| 1997 |
Gandara DR, Edelman MJ, Crowley JJ, Lau DH, Livingston RB. Phase II trial of edatrexate plus carboplatin in metastatic non-small-cell lung cancer: a Southwest Oncology Group study. Cancer Chemotherapy and Pharmacology. 41: 75-8. PMID 9443617 DOI: 10.1007/S002800050710 |
0.512 |
|
| 1997 |
Grozea PN, Crowley JJ, Canfield VA, Kingsbury L, Ross SW, Beltran GS, Laufman LR, Weiss GR, Livingston RB. Teniposide (VM-26) as a single drug treatment for patients with extensive small cell lung carcinoma: a Phase II study of the Southwest Oncology Group. Cancer. 80: 1029-33. PMID 9305702 DOI: 10.1002/(Sici)1097-0142(19970915)80:6<1029::Aid-Cncr4>3.0.Co;2-4 |
0.486 |
|
| 1997 |
Loehrer PJ, Chen M, Kim K, Aisner SC, Einhorn LH, Livingston R, Johnson D. Cisplatin, doxorubicin, and cyclophosphamide plus thoracic radiation therapy for limited-stage unresectable thymoma: an intergroup trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 15: 3093-9. PMID 9294472 DOI: 10.1200/Jco.1997.15.9.3093 |
0.304 |
|
| 1997 |
Livingston RB, Tsuchiva R, Fukushima M, Coltman CA. Summary of the proceedings of the United States-Japan lung cancer clinical trials summit Journal of Cancer Research and Clinical Oncology. 123: 461-466. PMID 9292711 DOI: 10.1007/Bf01372552 |
0.37 |
|
| 1997 |
Higano CS, Crowley JJ, Veith RV, Livingston RB. A phase II trial of intravenous vinorelbine in previously untreated patients with extensive small cell lung cancer, a Southwest Oncology Group study. Investigational New Drugs. 15: 153-6. PMID 9220295 DOI: 10.1023/A:1005869008452 |
0.53 |
|
| 1997 |
Livingston RB, Ellis GK, Gralow JR, Williams MA, White R, McGuirt C, Adamkiewicz BB, Long CA. Dose-intensive vinorelbine with concurrent granulocyte colony- stimulating factor support in paclitaxel-refractory metastatic breast cancer Journal of Clinical Oncology. 15: 1395-1400. PMID 9193331 DOI: 10.1200/Jco.1997.15.4.1395 |
0.482 |
|
| 1997 |
Murray N, Livingston R, Shepherd F, James K, Zee B, Langleben A, Kraut M, Bearden J, Goodwin J, Grafton C, Turrisi A, Walde D, Croft H, Ottaway J. 14 A randomized study of CODE plus thoracic irradiation versus alternating CAVEP for extensive stage small cell lung cancer (ESCLC): An intergroup study of the national cancer institute of Canada and the southwest oncology group Lung Cancer. 18: 6. DOI: 10.1016/S0169-5002(97)89293-8 |
0.427 |
|
| 1996 |
Figlin RA, Crowley JJ, Jacobs EL, Muirhead M, Goodwin JW, Rinehart JJ, Livingston RB. Evaluation of cisplatin, carboplatin, and etoposide in metastatic nonsmall cell lung carcinoma. A phase II study of the Southwest Oncology Group. Cancer. 78: 998-1003. PMID 8780537 DOI: 10.1002/(SICI)1097-0142(19960901)78:5<998::AID-CNCR9>3.0.CO;2-8 |
0.327 |
|
| 1996 |
Cain JM, Collins C, Petersdorf S, Figge DC, Tamimi HK, Greer BE, Livingston RB, Schlaerth JB, Golditch I. Phase II study of high-dose cisplatin, etoposide, and cyclophosphamide for refractory ovarian cancer American Journal of Obstetrics and Gynecology. 174: 1688-1694. PMID 8678128 DOI: 10.1016/S0002-9378(96)70198-9 |
0.337 |
|
| 1996 |
Tyshler L, Longton G, Ellis G, Livingston R. False Positive Tumor Markers: Elevation in Patients with Breast Cancer on FAC-type Chemotherapy and Correlation with the Development of Hand-foot Syndrome The International Journal of Biological Markers. 11: 203-206. DOI: 10.1177/172460089601100404 |
0.377 |
|
| 1996 |
Komaki R, Charles BS, William TS, Taylor S, David HJ, Livingston R, Emami B, Walter JC, Roger WB, Dar AR, Andrew TT, Cox JD. 96 Induction cisplatin/vinblastine decreased distant metastasis in unresectable squamous cell lung cancer (SCC): Failure patterns in RTOG 88-08/ECOG 4588 International Journal of Radiation Oncology Biology Physics. 36: 206. DOI: 10.1016/S0360-3016(97)85436-3 |
0.378 |
|
| 1995 |
Sause WT, Scott C, Taylor S, Johnson DH, Livingston R, Komaki R, Emami B, Curran WJ, Byhardt RW, Turrisi AT, Dar AR, Cox JD. Radiation Therapy Oncology Group (RTOG) 88–08 and Eastern Cooperative Oncology Group (ECOG) 4588: Preliminary Results of a Phase III Trial in Regionally Advanced, Unresectable Non-Small-Cell Lung Cancer Journal of the National Cancer Institute. 87: 198-205. PMID 7707407 DOI: 10.1093/Jnci/87.3.198 |
0.473 |
|
| 1995 |
Bunn PA, Crowley J, Kelly K, Hazuka MB, Beasley K, Upchurch C, Livingston R. Chemoradiotherapy with or without granulocyte-macrophage colony-stimulating factor in the treatment of limited-stage small-cell lung cancer: A prospective phase III randomized study of the southwest oncology group Journal of Clinical Oncology. 13: 1632-1641. PMID 7602352 DOI: 10.1200/JCO.1995.13.7.1632 |
0.341 |
|
| 1995 |
Williamson SK, Crowley JJ, Livingston RB, Panella TJ, Goodwin JW. Phase II trial and cost analysis of fazarabine in advanced non-small cell carcinoma of the lung: a Southwest Oncology Group study. Investigational New Drugs. 13: 67-71. PMID 7499111 DOI: 10.1007/Bf02614223 |
0.387 |
|
| 1995 |
Sause WT, Scott C, Taylor S, Johnson D, Livingston R, Komaki R, Cox JD, Emami B, Curran WJ, Byhardt RW, Dar AR, Turrisi AT. 109 RTOG 8808 ECOG 4588, preliminary analysis of a phase III trial in regionally advanced unresectable now small cell lung cancer with minimum three year follow-up International Journal of Radiation Oncology Biology Physics. 32: 195. DOI: 10.1016/0360-3016(95)97772-S |
0.423 |
|
| 1994 |
Loehrer PJ, Kim K, Aisner SC, Livingston R, Einhorn LH, Johnson D, Blum R. Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma: final results of an intergroup trial. The Eastern Cooperative Oncology Group, Southwest Oncology Group, and Southeastern Cancer Study Group. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 12: 1164-8. PMID 8201378 DOI: 10.1200/Jco.1994.12.6.1164 |
0.469 |
|
| 1994 |
Hazuka MB, Crowley JJ, Bunn PA, O'Rourke M, Braun TJ, Livingston RB. Daily low-dose cisplatin plus concurrent high-dose thoracic irradiation in locally advanced unresectable non-small-cell lung cancer: results of a phase II Southwest Oncology Group study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 12: 1814-20. PMID 8083705 DOI: 10.1200/JCO.1994.12.9.1814 |
0.333 |
|
| 1994 |
Rusch VW, Albain KS, Crowley JJ, Rice TW, Lonchyna V, McKenna R, Stelzer K, Livingston RB. Neoadjuvant therapy: a novel and effective treatment for stage IIIb non-small cell lung cancer. Southwest Oncology Group. The Annals of Thoracic Surgery. 58: 290-4; discussion 29. PMID 8067822 DOI: 10.1016/0003-4975(94)92195-4 |
0.501 |
|
| 1994 |
Livingston RB. Dose intensity and high dose therapy. Two different concepts. Cancer. 74: 1177-83. PMID 8039154 DOI: 10.1002/1097-0142(19940801)74:3+<1177::AID-CNCR2820741529>3.0.CO;2-7 |
0.349 |
|
| 1994 |
Petersdorf SH, Livingston RB. High dose chemotherapy for the treatment of malignant brain tumors. Journal of Neuro-Oncology. 20: 155-163. PMID 7807192 DOI: 10.1007/Bf01052725 |
0.442 |
|
| 1994 |
Wagner H, Kim K, Johnson DH, Komaki R, Sause W, Curran W, Livingston R, Turrisi AT. Daily (D) vs. twice-daily (BID) thoracic irradiation (TI) with concurrent cisplatinietoposide (PE) chemotherapy as initial therapy for patients with limited small cell lung cancer (LSCLC): Preliminary results of a phase III prospective intergroup trial International Journal of Radiation Oncology Biology Physics. 30: 178. DOI: 10.1016/0360-3016(94)90670-X |
0.486 |
|
| 1993 |
Buchholz TA, Austin-Seymour MM, Moe RE, Ellis GK, Livingston RB, Pelton JG, Griffin TW. Effect of delay in radiation in the combined modality treatment of breast cancer. International Journal of Radiation Oncology, Biology, Physics. 26: 23-35. PMID 8482628 DOI: 10.1016/0360-3016(93)90169-V |
0.435 |
|
| 1993 |
Ellis G, Livingston RB. Feasibility of dose-intensive continuous 5-fluorouracil, doxorubicin, and cyclophosphamide as adjuvant therapy for breast cancer. Cancer. 71: 392-396. PMID 8422633 DOI: 10.1002/1097-0142(19930115)71:2<392::Aid-Cncr2820710220>3.0.Co;2-Y |
0.466 |
|
| 1993 |
Chapman R, Crowley J, Lucas JG, Hom BL, Livingston RB, Vaughn CB, Hynes HE. Mitogauzone, cisplatin, and vinblastine in advanced non-small cell lung cancer: a Southwest Oncology Group study. Investigational New Drugs. 11: 91-92. PMID 8394299 DOI: 10.1007/Bf00873920 |
0.498 |
|
| 1993 |
Williamson SK, Crowley J, Livingston RB, Weiss G. Phase II trial of 6-thioguanine administered as 120 hour continuous infusion for refractory or recurrent small cell lung cancer. A Southwest Oncology Group study. Investigational New Drugs. 11: 81-3. PMID 8394296 DOI: 10.1007/BF00873917 |
0.413 |
|
| 1993 |
Albain KS, Crowley JJ, Hutchins L, Gandara D, O'Bryan RM, Von Hoff DD, Griffin B, Livingston RB. Predictors of survival following relapse or progression of small cell lung cancer. Southwest Oncology Group Study 8605 report and analysis of recurrent disease data base. Cancer. 72: 1184-91. PMID 8393365 DOI: 10.1002/1097-0142(19930815)72:4<1184::AID-CNCR2820720409>3.0.CO;2-Y |
0.373 |
|
| 1993 |
Grunberg SM, Crowley J, Livingston R, Gill I, Williamson SK, O'Rourke T, Braun T, Marshall ME, Weick JK, Balcerzak SP. Extended administration of oral etoposide and oral cyclophosphamide for the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 11: 1598-601. PMID 8393099 DOI: 10.1200/JCO.1993.11.8.1598 |
0.301 |
|
| 1993 |
Livingston RB, Crowley JJ, Thompson T, Williamson SK, Meyers FJ, O'Rourke T, Neefe JR. Prolonged, alternating chemotherapy for extensive small cell lung cancer. A Southwest oncology Group study. Cancer. 71: 3509-13. PMID 8387881 DOI: 10.1002/1097-0142(19930601)71:11<3509::AID-CNCR2820711108>3.0.CO;2-# |
0.442 |
|
| 1993 |
Gandara DR, Crowley J, Livingston RB, Perez EA, Taylor CW, Weiss G, Neefe JR, Hutchins LF, Roach RW, Grunberg SM, Braun TJ, Natale RB, Balcerzak SP. Evaluation of cisplatin intensity in metastatic non-small-cell lung cancer: a phase III study of the Southwest Oncology Group. Journal of Clinical Oncology. 11: 873-878. PMID 8387576 DOI: 10.1200/Jco.1993.11.5.873 |
0.42 |
|
| 1993 |
Rusch VW, Albain KS, Crowley JJ, Rice TW, Lonchyna V, McKenna R, Livingston RB, Griffin BR, Benfield JR. Surgical resection of stage IIIA and stage IIIB non-small-cell lung cancer after concurrent induction chemoradiotherapy. A Southwest Oncology Group trial. The Journal of Thoracic and Cardiovascular Surgery. 105: 97-106. DOI: 10.1016/S0022-5223(19)33853-X |
0.512 |
|
| 1992 |
Spence AM, Berger MS, Livingston RB, Ali-Osman F, Griffin B. Phase II evaluation of high-dose intravenous cisplatin for treatment of adult malignant gliomas recurrent after chloroethylnitrosourea failure. Journal of Neuro-Oncology. 12: 187-91. PMID 1560266 DOI: 10.1007/Bf00172671 |
0.412 |
|
| 1992 |
Livingston RB. Radiation-chemotherapy interactions in limited small cell lung cancer. Frontiers of Radiation Therapy and Oncology. 26: 72-82. PMID 1324878 DOI: 10.1159/000421057 |
0.407 |
|
| 1992 |
Williamson SK, Crowley JJ, Livingston R, Hantel A, Doroshow JH. Phase II trial of piroxantrone in advanced non-small cell carcinoma of the lung. A Southwest Oncology Group study. Investigational New Drugs. 10: 29-30. PMID 1318871 DOI: 10.1007/Bf01275476 |
0.416 |
|
| 1991 |
Albain KS, Crowley JJ, Livingston RB. Long-term survival and toxicity in small cell lung cancer. Expanded Southwest Oncology Group experience. Chest. 99: 1425-32. PMID 2036826 DOI: 10.1378/Chest.99.6.1425 |
0.482 |
|
| 1991 |
Press OW, Livingston R, Mortimer J, Collins C, Appelbaum F. Treatment of relapsed non-Hodgkin's lymphomas with dexamethasone, high-dose cytarabine, and cisplatin before marrow transplantation. Journal of Clinical Oncology. 9: 423-431. PMID 1999711 DOI: 10.1200/Jco.1991.9.3.423 |
0.416 |
|
| 1991 |
Ellis GK, Green S, Schulman S, Coltman CA, Hynes HE, Rivkin S, Livingston RB. Alternating weekly doxorubicin and 5‐fluorouracil/leucovorin followed by weekly doxorubicin and daily cyclophosphamide in stage IV breast cancer. A southwest oncology group study Cancer. 68: 934-939. PMID 1913489 DOI: 10.1002/1097-0142(19910901)68:5<934::Aid-Cncr2820680504>3.0.Co;2-N |
0.518 |
|
| 1991 |
Higano CS, Livingston RB, Crowley J, Goodwin JW, Barlogie B, Stuckey WJ. A weekly cisplatin-based induction regimen for extensive non-small cell lung cancer: A Southwest Oncology Group study Cancer. 67: 2439-2442. PMID 1849785 DOI: 10.1002/1097-0142(19910515)67:10<2439::Aid-Cncr2820671007>3.0.Co;2-6 |
0.497 |
|
| 1991 |
Goodman GE, Crowley J, Livingston RB, Rivkin SE, Albain K, McCulloch JH. Treatment of limited small-cell lung cancer with concurrent etoposide/cisplatin and radiotherapy followed by intensification with high-dose cyclophosphamide: a Southwest Oncology Group study. Journal of Clinical Oncology. 9: 453-457. PMID 1847967 DOI: 10.1200/Jco.1991.9.3.453 |
0.488 |
|
| 1991 |
Albain KS, Crowley JJ, LeBlanc M, Livingston RB. Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 9: 1618-26. PMID 1651993 DOI: 10.1200/Jco.1991.9.9.1618 |
0.438 |
|
| 1991 |
Grunberg SM, Crowley JJ, Livingston RB, Muggia FM, MacDonald JS, Williamson SK, Stephens RL. Treatment of non-small-cell lung cancer with vinblastine and very high-dose cisplatin. A Southwest Oncology Group study. Cancer Chemotherapy and Pharmacology. 28: 211-3. PMID 1649706 DOI: 10.1007/Bf00685511 |
0.439 |
|
| 1991 |
Weick JK, Crowley J, Natale RB, Hom BL, Rivkin S, Coltman CA, Taylor SA, Livingston RB. A randomized trial of five cisplatin-containing treatments in patients with metastatic non-small-cell lung cancer: a Southwest Oncology Group study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 9: 1157-62. PMID 1646292 DOI: 10.1200/Jco.1991.9.7.1157 |
0.509 |
|
| 1991 |
Ellis GK, Livingston RB, Crowley J, Goodwin JW, Hutchins L, Allen A. Cisplatin and novobiocin in the treatment of non-small cell lung cancer. A Southwest Oncology Group study. Cancer. 67: 2969-2973. PMID 1646065 DOI: 10.1002/1097-0142(19910615)67:12<2969::Aid-Cncr2820671205>3.0.Co;2-M |
0.468 |
|
| 1990 |
Loehrer PJ, Perez CA, Roth LM, Greco FA, Livingston RB, Einhorn LH. Chemotherapy for advanced thymoma. Preliminary results of an intergroup study. Annals of Internal Medicine. 113: 520-524. PMID 2203292 DOI: 10.7326/0003-4819-113-7-520 |
0.472 |
|
| 1990 |
Taylor CW, Crowley J, Williamson SK, Miller TP, Taylor SA, Giri TG, Stephens RL, Livingston RB. Treatment of small-cell lung cancer with an alternating chemotherapy regimen given at weekly intervals: a Southwest Oncology Group pilot study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 8: 1811-7. PMID 2172473 DOI: 10.1200/Jco.1990.8.11.1811 |
0.396 |
|
| 1990 |
Albain KS, Crowley JJ, LeBlanc M, Livingston RB. Determinants of improved outcome in small-cell lung cancer: an analysis of the 2,580-patient Southwest Oncology Group data base. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 8: 1563-74. PMID 2167954 DOI: 10.1200/Jco.1990.8.9.1563 |
0.389 |
|
| 1990 |
Goodman GE, Crowley JJ, Blasko JC, Livingston RB, Beck TM, Demattia MD, Bukowski RM. Treatment of limited small-cell lung cancer with etoposide and cisplatin alternating with vincristine, doxorubicin, and cyclophosphamide versus concurrent etoposide, vincristine, doxorubicin, and cyclophosphamide and chest radiotherapy: a Southwest Oncology Group Study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 8: 39-47. PMID 2153194 DOI: 10.1200/Jco.1990.8.1.39 |
0.363 |
|
| 1989 |
Collins C, Mortimer J, Livingston RB. High-dose cyclophosphamide in the treatment of refractory lymphomas and solid tumor malignancies Cancer. 63: 228-232. PMID 2910431 DOI: 10.1002/1097-0142(19890115)63:2<228::Aid-Cncr2820630204>3.0.Co;2-3 |
0.414 |
|
| 1989 |
Ellis GK, Green S, Schulman S, Tranum BL, Goldberg RS, Livingston RB. Combination chemotherapy and high-dose cyclophosphamide intensification for poor prognosis breast cancer. A Southwest Oncology Group Study. Cancer. 64: 2409-15. PMID 2684382 DOI: 10.1002/1097-0142(19891215)64:12<2409::Aid-Cncr2820641202>3.0.Co;2-T |
0.522 |
|
| 1989 |
Higano CS, Livingston RB. Oral dipyridamole and methotrexate in human solid tumors: a toxicity trial. Cancer Chemotherapy and Pharmacology. 23: 259-262. PMID 2647313 DOI: 10.1007/Bf00451653 |
0.377 |
|
| 1989 |
Goodman GR, Livingston RB. Small cell lung cancer. Dm Disease-a-Month. 35: 774-825. PMID 2556255 DOI: 10.1016/0011-5029(89)90023-0 |
0.458 |
|
| 1989 |
Livingston RB. Stage IV non-small-cell lung cancer: the guides are perplexed. Journal of Clinical Oncology. 7: 1591-1593. PMID 2553878 DOI: 10.1200/Jco.1989.7.11.1591 |
0.394 |
|
| 1989 |
Collins C, Higano CS, Livingston RB, Griffin BR, Keppen MD, Miller TP. Cyclophosphamide, vincristine, cisplatin, VP-16 and radiation therapy in extensive small-cell lung cancer. A Southwest Oncology Group Study. Cancer Chemotherapy and Pharmacology. 24: 128-132. PMID 2543513 DOI: 10.1007/Bf00263134 |
0.501 |
|
| 1989 |
Ellis G, Ferguson M, Yamanaka E, Livingston RB, Gown AM. Monoclonal antibodies for detection of occult carcinoma cells in bone marrow of breast cancer patients. Cancer. 63: 2509-2514. PMID 2470494 DOI: 10.1002/1097-0142(19890615)63:12<2509::Aid-Cncr2820631225>3.0.Co;2-K |
0.392 |
|
| 1989 |
Rusch VW, Griffin BR, Livingston RB. The role of prophylactic cranial irradiation in regionally advanced non-small cell lung cancer. A Southwest Oncology Group Study. The Journal of Thoracic and Cardiovascular Surgery. 98: 535-539. DOI: 10.1016/S0022-5223(19)34355-7 |
0.506 |
|
| 1989 |
Livingston RB, Goodman GE. Small cell lung cancer. Current Problems in Cancer. 13: 7-54. DOI: 10.1016/0147-0272(89)90014-7 |
0.458 |
|
| 1988 |
Griffin BR, Livingston RB, Stewart GR, Higano C, Russell KJ, Griffin TW, Laramore GE. Prophylactic cranial irradiation for limited non-small cell lung cancer. Cancer. 62: 36-9. PMID 2838149 DOI: 10.1002/1097-0142(19880701)62:1<36::Aid-Cncr2820620109>3.0.Co;2-I |
0.451 |
|
| 1988 |
Mira JG, Chen TT, Livingston RB, Wilson HE. Outcome of prophylactic and therapeutic cranial irradiation in disseminated small cell lung carcinoma: a Southwest Oncology Group Study. International Journal of Radiation Oncology Biology Physics. 14: 861-865. PMID 2834310 DOI: 10.1016/0360-3016(88)90006-5 |
0.366 |
|
| 1988 |
Livingston RB. Mopidamol in non-small cell lung cancer: anti-oncogene or accident? Journal of the National Cancer Institute. 80: 77-78. PMID 2830406 DOI: 10.1093/Jnci/80.2.77 |
0.37 |
|
| 1987 |
Livingston RB, Schulman S, Griffin BR, Tranum BL, Rivkin SE, Goldberg RS, Fabian CJ, Hammond N, Hynes H. Combination chemotherapy and systemic irradiation consolidation for poor prognosis breast cancer. Cancer. 59: 1249-1254. PMID 3545430 DOI: 10.1002/1097-0142(19870401)59:7<1249::Aid-Cncr2820590703>3.0.Co;2-K |
0.534 |
|
| 1987 |
Kies MS, Mira JG, Crowley JJ, Chen TT, Pazdur R, Grozea PN, Rivkin SE, Coltman CA, Ward JH, Livingston RB. Multimodal therapy for limited small-cell lung cancer: a randomized study of induction combination chemotherapy with or without thoracic radiation in complete responders; and with wide-field versus reduced-field radiation in partial responders: a Southwest Oncology Group Study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 5: 592-600. PMID 3031226 DOI: 10.1200/JCO.1987.5.4.592 |
0.388 |
|
| 1987 |
Livingston RB, Griffin BR, Higano CS, Laramore GE, Rivkin SE, Goldberg RS, Schulman SF. Combined treatment with chemotherapy and neutron irradiation for limited non-small-cell lung cancer: a Southwest Oncology Group Study. Journal of Clinical Oncology. 5: 1716-1724. PMID 2824705 DOI: 10.1200/Jco.1987.5.11.1716 |
0.492 |
|
| 1987 |
Press OW, Livingston R. Management of Malignant Pericardial Effusion and Tamponade Jama. 257: 1088-1092. DOI: 10.1001/Jama.1987.03390080078037 |
0.307 |
|
| 1986 |
Livingston RB. Small-cell lung cancer--whither late intensification? Journal of Clinical Oncology. 4: 1437-1438. PMID 3020180 DOI: 10.1200/Jco.1986.4.10.1437 |
0.381 |
|
| 1986 |
Miller TP, Chen TT, Coltman CA, O'Bryan RM, Vance RB, Weiss GB, Fletcher WS, Stephens RL, Livingston RB. Effect of alternating combination chemotherapy on survival of ambulatory patients with metastatic large-cell and adenocarcinoma of the lung. A Southwest Oncology Group Study. Journal of Clinical Oncology. 4: 502-508. PMID 3007683 DOI: 10.1200/Jco.1986.4.4.502 |
0.496 |
|
| 1986 |
Livingston RB. Current Chemotherapy of Small Cell Lung Cancer Chest. 89: 258. PMID 3007042 DOI: 10.1378/Chest.89.4_Supplement.258S |
0.494 |
|
| 1985 |
Mortimer J, Flournoy N, Livingston RB, Stephens RL. Aggressive adriamycin-containing regimen (PM-FAC) in estrogen receptor-negative disseminated breast cancer. Results of a Southwest Oncology Group trial Cancer. 56: 2376-2380. PMID 3899347 |
0.397 |
|
| 1984 |
Livingston RB, Mira JG, Chen TT, McGavran M, Costanzi JJ, Samson M. Combined modality treatment of extensive small cell lung cancer: a Southwest Oncology Group study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 2: 585-90. PMID 6327927 DOI: 10.1200/JCO.1984.2.6.585 |
0.428 |
|
| 1984 |
Livingston RB, Stephens RL, Bonnet JD, Grozea PN, Lehane DE. Long-term survival and toxicity in small cell lung cancer: Southwest oncology group study☆ The American Journal of Medicine. 77: 415-417. PMID 6089560 DOI: 10.1016/0002-9343(84)90095-0 |
0.458 |
|
| 1983 |
Livingston RB. Breast cancer and response to chemotherapy: a possible relationship of hormone receptors and doxorubicin. Cancer Treatment Reviews. 9: 229-36. PMID 7159879 DOI: 10.1016/S0305-7372(82)80008-X |
0.322 |
|
| 1983 |
Budd GT, Webster KD, Reimer RR, Martimbeau P, Livingston RB. Treatment of advanced ovarian cancer with cisplatin, adriamycin, and cyclophosphamide: effect of treatment and incidence of intracranial metastases. Journal of Surgical Oncology. 24: 192-5. PMID 6685214 DOI: 10.1002/Jso.2930240309 |
0.447 |
|
| 1982 |
Mira JG, Livingston RB, Moore TN, Chen T, Batley F, Bogardus CR, Considine B, Mansfield CM, Schlosser J, Seydel HG. Influence of chest radiotherapy in frequency and patterns of chest relapse in disseminated small cell lung carcinoma. A Southwest Oncology Group Study. Cancer. 50: 1266-72. PMID 6286089 DOI: 10.1002/1097-0142(19821001)50:7<1266::Aid-Cncr2820500708>3.0.Co;2-0 |
0.364 |
|
| 1982 |
Mortimer J, Bukowski RM, Montie J, Hewlett JS, Livingston RB. VP16-213, cisplatinum, and adriamycin salvage therapy of refractory and/or recurrent nonseminomatous germ cell neoplasms. Cancer Chemotherapy and Pharmacology. 7: 215-8. PMID 6282486 DOI: 10.1007/BF00254553 |
0.317 |
|
| 1982 |
Livingston RB, McCracken JD, Trauth CJ, Chen T. Isolated pleural effusion in small cell lung carcinoma: favorable prognosis. A review of the Southwest Oncology Group experience. Chest. 81: 208-11. PMID 6276105 DOI: 10.1378/CHEST.81.2.208 |
0.368 |
|
| 1982 |
Bukowski RM, Schacter LP, Groppe CW, Hewlett JS, Weick JK, Livingston RB. Phase II trial of 5-fluorouracil, adriamycin, mitomycin C, and streptozotocin (FAM-S) in pancreatic carcinoma. Cancer. 50: 197-200. PMID 6211223 DOI: 10.1002/1097-0142(19820715)50:2<197::AID-CNCR2820500204>3.0.CO;2-N |
0.308 |
|
| 1982 |
Theodors A, Bukowski RM, Hewlett JS, Livingston RB, Weick JK. Intermittent regional infusion of chemotherapy for pancreatic adenocarcinoma. Phase I and II pilot study. American Journal of Clinical Oncology. 5: 555-558. DOI: 10.1097/00000421-198205050-00017 |
0.433 |
|
| 1981 |
Livingston RB. Breast cancer trials--a new initiative Bmj. 282: 563-563. DOI: 10.1136/BMJ.282.6263.563 |
0.316 |
|
| 1980 |
Blumenschein GR, Hortobagyi GN, Richman SP, Gutterman JU, Tashima CK, Buzdar AU, Burgess MA, Livingston RB, Hersh EM. Alternating noncross-resistant combination chemotherapy and active nonspecific immunotherapy with BCG or MER-BCG for advanced breast carcinoma Cancer. 45: 742-749. PMID 6986970 DOI: 10.1002/1097-0142(19800215)45:4<742::AID-CNCR2820450422>3.0.CO;2-X |
0.427 |
|
| 1980 |
McCracken JD, Heilbrun L, White J, Reed R, Samson M, Saiers JH, Stephens R, Stuckey WJ, Bickers J, Livingston R. Combination chemotherapy, radiotherapy, and BCG immunotherapy in extensive (metastatic) small cell carcinoma of the lung. A Southwest Oncology Group study Cancer. 46: 2335-2340. PMID 6254629 DOI: 10.1002/1097-0142(19801201)46:11<2335::AID-CNCR2820461102>3.0.CO;2-G |
0.38 |
|
| 1980 |
Mouridsen HT, Rose C, Palshof T, Greenspan E, Price LA, Hill B, Livingston R, Powles T. CHEMOTHERAPY AND SURVIVAL IN BREAST CANCER The Lancet. 315: 982-984. PMID 6103323 DOI: 10.1016/S0140-6736(80)91429-4 |
0.379 |
|
| 1980 |
Mira JG, Livingston RB, Moore TN. Influence of radiotherapy in patterns of relapse in extensive small cell carcinoma of lung treated by combined modality: Clinical implications International Journal of Radiation Oncology Biology Physics. 6: 1337-1338. DOI: 10.1016/0360-3016(80)90415-0 |
0.344 |
|
| 1979 |
Bedikian AY, Staab R, Livingston R, Valdivieso M, Burgess MA, Bodey GP. Chemotherapy for adenocarcinoma of the lung with 5-fluorouracil, cyclophosphamide, and CCNU (FCC) Cancer. 44: 858-863. PMID 476597 DOI: 10.1002/1097-0142(197909)44:3<858::AID-CNCR2820440310>3.0.CO;2-P |
0.333 |
|
| 1979 |
Hortobagyi GN, Blumenschein GR, Tashima CK, Buzdar AU, Burgess MA, Livingston RB, Valdivieso M, Gutterman JU, Hersh EM, Bodey GP. Ftorafur, adriamycin, cyclophosphamide and BCG in the treatment of metastatic breast cancer Cancer. 44: 398-405. PMID 383255 DOI: 10.1002/1097-0142(197908)44:2<398::Aid-Cncr2820440205>3.0.Co;2-T |
0.499 |
|
| 1979 |
Sulkes A, Livingston RB, Murphy WK. Tritiated thymidine labeling index and response in human breast cancer. Journal of the National Cancer Institute. 62: 513-5. PMID 283280 DOI: 10.1093/JNCI/62.3.513 |
0.365 |
|
| 1978 |
Buzdar AU, Tashima CK, Blumenschein GR, Hortobagyi GN, Yap HY, Krutchik AN, Bodey GP, Livingston RB. Mitomycin-C and megestrol acetate in treatment of breast cancer refractory to hormonal and combination chemotherapy. Cancer. 41: 392-5. PMID 630529 DOI: 10.1002/1097-0142(197802)41:2<392::AID-CNCR2820410202>3.0.CO;2-7 |
0.403 |
|
| 1978 |
Livingston RB, Moore TN, Heilbrun L, Bottomley R, Lehane D, Rivkin SE, Thigpen T. Small-cell carcinoma of the lung: combined chemotherapy and radiation: a Southwest Oncology Group study. Annals of Internal Medicine. 88: 194-9. PMID 204239 DOI: 10.7326/0003-4819-88-2-194 |
0.355 |
|
| 1977 |
Suen JY, Richman SP, Livingston RB, Hersh EM, Craig R, Tonymon K. Results of BCG adjuvant immunotherapy in 100 patients with epidermoid carcinoma of the head and neck. American Journal of Surgery. 134: 474-8. PMID 911030 DOI: 10.1016/0002-9610(77)90381-6 |
0.388 |
|
| 1976 |
Livingston RB. Selecting chemotherapy for metastatic breast cancer. Postgraduate Medicine. 59: 97-100. PMID 1264894 DOI: 10.1080/00325481.1976.11714297 |
0.38 |
|
| 1976 |
Rodriguez V, Gottlieb J, Burgess MA, Livingston R, Wheeler W, Spitzer G, Bodey GP, Blumenschein GR, Freireich EJ. Phase I studies with Baker's Antifol (BAF) (NSC 139105). Cancer. 38: 690-4. PMID 974989 DOI: 10.1002/1097-0142(197608)38:2<690::AID-CNCR2820380212>3.0.CO;2-X |
0.306 |
|
| 1976 |
Gutterman JU, Cardenas JO, Blumenschein GR, Hortobagyi G, Burgess MA, Livingston RB, Mavligit GM, Freireich EJ, Gottlieb JA, Hersh EM. Chemoimmunotherapy of advanced breast cancer: Prolongation of remission and survival with BCG British Medical Journal. 2: 1222-1225. PMID 791447 DOI: 10.1136/Bmj.2.6046.1222 |
0.514 |
|
| 1976 |
Livingston RB, Fee WH, Einhorn LH, Burgess MA, Freireich EJ, Gottlieb JA, Farber MO. BACON (Bleomycin, adriamycin, CCNU, oncovin and nitrogen mustard) in squamous lung cancer. Experience in fifty patients Cancer. 37: 1237-1242. PMID 56980 DOI: 10.1002/1097-0142(197603)37:3<1237::AID-CNCR2820370302>3.0.CO;2-Z |
0.34 |
|
| 1976 |
Einhorn LH, Fee WH, Farber MO, Livingston RB, Gottlieb JA. Improved Chemotherapy for Small-Cell Undifferentiated Lung Cancer Jama: the Journal of the American Medical Association. 235: 1225-1229. PMID 55504 DOI: 10.1001/jama.1976.03260380019019 |
0.4 |
|
| 1975 |
Carter SK, Livingston RB. Cyclophosphamide in solid tumors Cancer Treatment Reviews. 2: 295-322. PMID 766966 DOI: 10.1016/S0305-7372(75)80010-7 |
0.511 |
|
| 1975 |
Livingston RB, Einhorn LH, Bodey GP, Burgess MA, Freireich EJ, Gottlieb JA. Comb (cyclophosphamide, oncovin, methyl ccnu, and bleomycin): a four drug combination in solid tumors Cancer. 36: 327-332. PMID 50870 DOI: 10.1002/1097-0142(197508)36:2<327::AID-CNCR2820360206>3.0.CO;2-U |
0.338 |
|
| 1973 |
Carter SK, Livingston RB. Single-Agent Therapy for Hodgkin's Disease Archives of Internal Medicine. 131: 377-387. PMID 4631683 DOI: 10.1001/Archinte.1973.00320090067007 |
0.569 |
|
| 1973 |
Blum RH, Livingston RB, Carter SK. Hexamethylmelamine--a new drug with activity in solid tumors. European Journal of Cancer. 9: 195-202. PMID 4595749 DOI: 10.1016/S0014-2964(73)80019-2 |
0.661 |
|
| 1970 |
Livingston RB, Venditti JM, Cooney DA, Carter SK. Glutamine antagonists in chemotherapy. Advances in Pharmacology and Chemotherapy. 8: 57-120. PMID 4400179 DOI: 10.1016/S1054-3589(08)60594-3 |
0.464 |
|
| Show low-probability matches. |
